<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Transl Autoimmun</journal-id><journal-id journal-id-type="iso-abbrev">J Transl Autoimmun</journal-id><journal-title-group><journal-title>Journal of Translational Autoimmunity</journal-title></journal-title-group><issn pub-type="epub">2589-9090</issn><publisher><publisher-name>Elsevier</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11786776</article-id><article-id pub-id-type="pii">S2589-9090(25)00003-6</article-id><article-id pub-id-type="doi">10.1016/j.jtauto.2025.100268</article-id><article-id pub-id-type="publisher-id">100268</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research paper</subject></subj-group></article-categories><title-group><article-title>Across ancestries, HLA-B&#x02217;08:01&#x0223c;DRB1&#x02217;03:01 (DR3) and HLA-DQA&#x02217;01:02 (DR2) increase the risk to develop juvenile-onset systemic lupus erythematosus through low complement C4 levels</article-title></title-group><contrib-group><contrib contrib-type="author" id="au1"><name><surname>Renaudineau</surname><given-names>Yves</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff2" ref-type="aff">b</xref><xref rid="cor2" ref-type="corresp">&#x0204e;&#x0204e;</xref><xref rid="fn1" ref-type="fn">1</xref></contrib><contrib contrib-type="author" id="au2"><name><surname>Charras</surname><given-names>Amandine</given-names></name><xref rid="aff3" ref-type="aff">c</xref><xref rid="fn1" ref-type="fn">1</xref></contrib><contrib contrib-type="author" id="au3"><name><surname>Natoli</surname><given-names>Valentina</given-names></name><xref rid="aff3" ref-type="aff">c</xref><xref rid="aff4" ref-type="aff">d</xref><xref rid="aff5" ref-type="aff">e</xref></contrib><contrib contrib-type="author" id="au4"><name><surname>Congy-Jolivet</surname><given-names>Nicolas</given-names></name><xref rid="aff1" ref-type="aff">a</xref><xref rid="aff6" ref-type="aff">f</xref></contrib><contrib contrib-type="author" id="au5"><name><surname>Haldenby</surname><given-names>Sam</given-names></name><xref rid="aff7" ref-type="aff">g</xref></contrib><contrib contrib-type="author" id="au6"><name><surname>Liu</surname><given-names>Xuan</given-names></name><xref rid="aff7" ref-type="aff">g</xref></contrib><contrib contrib-type="author" id="au7"><name><surname>Fang</surname><given-names>Yongxiang</given-names></name><xref rid="aff7" ref-type="aff">g</xref></contrib><contrib contrib-type="author" id="au8"><name><surname>Smith</surname><given-names>Eve MD.</given-names></name><xref rid="aff3" ref-type="aff">c</xref><xref rid="aff8" ref-type="aff">h</xref></contrib><contrib contrib-type="author" id="au9"><name><surname>Beresford</surname><given-names>Michael W.</given-names></name><xref rid="aff3" ref-type="aff">c</xref><xref rid="aff8" ref-type="aff">h</xref></contrib><contrib contrib-type="author" id="au10"><name><surname>Hedrich</surname><given-names>Christian M.</given-names></name><email>christian.hedrich@liverpool.ac.uk</email><xref rid="aff3" ref-type="aff">c</xref><xref rid="aff8" ref-type="aff">h</xref><xref rid="cor1" ref-type="corresp">&#x0204e;</xref></contrib><on-behalf-of>on behalf of the </on-behalf-of><contrib contrib-type="author"><collab>UK jSLE Cohort Study Group<contrib-group><contrib contrib-type="author" id="au11"><name><surname>Roberts</surname><given-names>Carla</given-names></name><xref rid="aff9" ref-type="aff">i</xref></contrib><contrib contrib-type="author" id="au12"><name><surname>Al-Abadi</surname><given-names>Eslam</given-names></name><xref rid="aff10" ref-type="aff">j</xref></contrib><contrib contrib-type="author" id="au13"><name><surname>Armon</surname><given-names>Kate</given-names></name><xref rid="aff11" ref-type="aff">k</xref></contrib><contrib contrib-type="author" id="au14"><name><surname>Bailey</surname><given-names>Kathryn</given-names></name><xref rid="aff12" ref-type="aff">l</xref></contrib><contrib contrib-type="author" id="au15"><name><surname>Ciurtin</surname><given-names>Coziana</given-names></name><xref rid="aff13" ref-type="aff">m</xref></contrib><contrib contrib-type="author" id="au16"><name><surname>Gardner-Medwin</surname><given-names>Janet</given-names></name><xref rid="aff14" ref-type="aff">n</xref></contrib><contrib contrib-type="author" id="au17"><name><surname>Haslam</surname><given-names>Kirsty</given-names></name><xref rid="aff15" ref-type="aff">o</xref></contrib><contrib contrib-type="author" id="au18"><name><surname>Hawley</surname><given-names>Daniel P.</given-names></name><xref rid="aff16" ref-type="aff">p</xref></contrib><contrib contrib-type="author" id="au19"><name><surname>Leahy</surname><given-names>Alice</given-names></name><xref rid="aff17" ref-type="aff">q</xref></contrib><contrib contrib-type="author" id="au20"><name><surname>Leone</surname><given-names>Valentina</given-names></name><xref rid="aff18" ref-type="aff">r</xref></contrib><contrib contrib-type="author" id="au21"><name><surname>McErlane</surname><given-names>Flora</given-names></name><xref rid="aff19" ref-type="aff">s</xref></contrib><contrib contrib-type="author" id="au22"><name><surname>Modgil</surname><given-names>Gita</given-names></name><xref rid="aff20" ref-type="aff">t</xref></contrib><contrib contrib-type="author" id="au23"><name><surname>Pilkington</surname><given-names>Clarissa</given-names></name><xref rid="aff21" ref-type="aff">u</xref></contrib><contrib contrib-type="author" id="au24"><name><surname>Ramanan</surname><given-names>Athimalaipet V.</given-names></name><xref rid="aff22" ref-type="aff">v</xref></contrib><contrib contrib-type="author" id="au25"><name><surname>Rangaraj</surname><given-names>Satyapal</given-names></name><xref rid="aff23" ref-type="aff">w</xref></contrib><contrib contrib-type="author" id="au26"><name><surname>Riley</surname><given-names>Phil</given-names></name><xref rid="aff24" ref-type="aff">x</xref></contrib><contrib contrib-type="author" id="au27"><name><surname>Sridhar</surname><given-names>Arani</given-names></name><xref rid="aff25" ref-type="aff">y</xref></contrib><aff id="aff9"><label>i</label>Department of Women's &#x00026; Children's Health, Institute of Life Course and Medical Sciences, University of Liverpool, United Kingdom</aff><aff id="aff10"><label>j</label>Department of Rheumatology, Birmingham Children's Hospital, Birmingham, United Kingdom</aff><aff id="aff11"><label>k</label>Department of Paediatric Rheumatology, Cambridge University Hospitals, Cambridge, United Kingdom</aff><aff id="aff12"><label>l</label>Department of Paediatric Rheumatology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom</aff><aff id="aff13"><label>m</label>Centre for Adolescent Rheumatology, University College London, London, United Kingdom</aff><aff id="aff14"><label>n</label>Department of Child Health, University of Glasgow, Glasgow, United Kingdom</aff><aff id="aff15"><label>o</label>Department of Paediatrics, Bradford Royal Infirmary, Bradford, United Kingdom</aff><aff id="aff16"><label>p</label>Department of Paediatric Rheumatology, Sheffield Children's Hospital, Sheffield, United Kingdom</aff><aff id="aff17"><label>q</label>Department of Paediatric Rheumatology, Southampton General Hospital, Southampton, United Kingdom</aff><aff id="aff18"><label>r</label>Department of Paediatric Rheumatology, Leeds Children Hospital, Leeds, United Kingdom</aff><aff id="aff19"><label>s</label>Paediatric Rheumatology, Great North Children's Hospital, Royal Victoria Infirmary, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom</aff><aff id="aff20"><label>t</label>Department of Paediatrics, Musgrove Park Hospital, Taunton, United Kingdom</aff><aff id="aff21"><label>u</label>Department of Paediatric Rheumatology, Great Ormond Street Hospital, London, United Kingdom</aff><aff id="aff22"><label>v</label>University Hospitals Bristol NHS Foundation Trust &#x00026; Bristol Medical School, University of Bristol, Bristol, United Kingdom</aff><aff id="aff23"><label>w</label>Department of Paediatric Rheumatology, Nottingham University Hospitals, Nottingham, United Kingdom</aff><aff id="aff24"><label>x</label>Department of Paediatric Rheumatology, Royal Manchester Children's Hospital, Manchester, United Kingdom</aff><aff id="aff25"><label>y</label>Department of Paediatrics, Leicester Royal Infirmary, Leicester, United Kingdom</aff></contrib-group></collab></contrib><aff id="aff1"><label>a</label>Immunology Department Laboratory, Referral Medical Biology Laboratory, Institut F&#x000e9;d&#x000e9;ratif de Biologie, Toulouse University Hospital Centre, France</aff><aff id="aff2"><label>b</label>INFINITy, Toulouse Institute for Infectious and Inflammatory Diseases, INSERM U1291, CNRS U5051, University Toulouse III, Toulouse, France</aff><aff id="aff3"><label>c</label>Department of Women's &#x00026; Children's Health, Institute of Life Course and Medical Sciences, University of Liverpool, United Kingdom</aff><aff id="aff4"><label>d</label>Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili, Universit&#x000e0; degli Studi di Genova, Genoa, Italy</aff><aff id="aff5"><label>e</label>UOC Reumatologia e Malattie Autoinfiammatorie, IRCCS Istituto Giannina Gaslini, Genoa, Italy</aff><aff id="aff6"><label>f</label>CRCT, INSERM, UMR, 1037, University Toulouse III, Toulouse, France</aff><aff id="aff7"><label>g</label>Centre for Genomic Research, Shared Research Facilities, University of Liverpool, United Kingdom</aff><aff id="aff8"><label>h</label>Department of Rheumatology, Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom</aff></contrib-group><author-notes><corresp id="cor1"><label>&#x0204e;</label>Corresponding author. Department of Women's &#x00026; Children's Health, Institute of Life Course and Medical Sciences, University of Liverpool, United Kingdom <email>christian.hedrich@liverpool.ac.uk</email></corresp><corresp id="cor2"><label>&#x0204e;&#x0204e;</label>Corresponding author. Immunology Department Laboratory, Referral Medical Biology Laboratory, Institut F&#x000e9;d&#x000e9;ratif de Biologie, Toulouse University Hospital Centre, France</corresp><fn id="fn1"><label>1</label><p id="ntpara0010">Equal contribution.</p></fn></author-notes><pub-date pub-type="pmc-release"><day>07</day><month>1</month><year>2025</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on <pub-date
						pub-type="epub">.--><pub-date pub-type="collection"><month>6</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>07</day><month>1</month><year>2025</year></pub-date><volume>10</volume><elocation-id>100268</elocation-id><history><date date-type="received"><day>23</day><month>10</month><year>2024</year></date><date date-type="rev-recd"><day>3</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>3</day><month>1</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 The Authors</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).</license-p></license></permissions><abstract id="abs0010"><sec><title>Objective</title><p>Systemic lupus erythematosus (SLE) is a systemic autoimmune/inflammatory disease with a strong genetic component. Genetic burden is higher in children when compared to patients with adult-onset SLE, contributing to earlier disease expression and more severe phenotypes. The human leukocyte antigen (HLA) cluster on chromosome 6p21.3 is among the most variable genomic regions, representing a major risk-factor for SLE in adults. Its impact on juvenile-onset (j)SLE remains largely unstudied.</p></sec><sec><title>Methods</title><p>High-resolution sequencing of HLA class I (A, B, C), class II (DRB1, DQA1, DQB1) and class III (complement <italic>C2</italic>) was undertaken in the multi-ancestral UK JSLE Cohort including participants of Caucasian (n&#x000a0;=&#x000a0;151, 48.8&#x000a0;%), Asian (n&#x000a0;=&#x000a0;108, 35.0&#x000a0;%) and African/Caribbean (n&#x000a0;=&#x000a0;50, 16.2&#x000a0;%) descent. Considering ancestral variation, clinical associations were tested at the level of alleles (2-field resolution), associated HLA protein sequences (antigen binding domains, 4-field resolution), and extended haplotypes (DRh).</p></sec><sec><title>Results</title><p>Although important ancestral recombination was reported for HLA-DR2 and -DR3 haplotypes, risk associated with jSLE was conserved at related alleles (DR2h: DRB1&#x02217;15:01, DQA&#x02217;01:02, DQB1&#x02217;06:02; DR3h: C&#x02217;07:02 [Asian], B&#x02217;08:01, <italic>C2</italic> rs9332730 [Asian], DRB1&#x02217;03:01). HLA-DR7 haplotypes (DRB1&#x02217;07:01, OR&#x000a0;=&#x000a0;0.44, 95&#x000a0;% CI:0.27&#x02013;0.72, p&#x000a0;=&#x000a0;0.0004; DQA1&#x02217;02:01, OR&#x000a0;=&#x000a0;0.34, 95&#x000a0;% CI:0.21&#x02013;0.56, p&#x000a0;=&#x000a0;1.8&#x000a0;&#x000d7;&#x000a0;10<sup>&#x02212;6</sup>) protect Asians from jSLE development. Among 23 clinical variables recorded, the main association was found between low levels of complement C4 in Caucasian carriers of HLA-DR3h. This was not the case in Asians due to recombination with HLA-C&#x02217;07:02 and integration of the <italic>C2</italic> rs9332730 minor allele. Low C4 serum levels associated with HLA-DQA1&#x02217;01:02 (DR2h) in Caucasians after excluding HLA-DR3h carriers from the analysis. An association between low white blood cell counts and HLA-A&#x02217;03:01P was observed across ancestries.</p></sec><sec><title>Conclusion</title><p>Genetic variation in the <italic>HLA</italic> cluster associates with organ domain involvement (hematological) and complement levels in jSLE. Lupus-associated <italic>HLA</italic> haplotypes vary between ancestral groups, underscoring the importance of multi-ancestral approaches to genetic studies in SLE and other autoimmune/inflammatory diseases.</p></sec></abstract><abstract abstract-type="author-highlights" id="abs0015"><title>Highlights</title><p><list list-type="simple" id="ulist0010"><list-item id="u0010"><label>&#x02022;</label><p id="p0010">Lupus-associated HLA haplotypes vary between ancestral groups.</p></list-item><list-item id="u0015"><label>&#x02022;</label><p id="p0015">Across ancestries, HLA-DR2 and -DR3 haplotypes act as jSLE risk factors.</p></list-item><list-item id="u0020"><label>&#x02022;</label><p id="p0020">In Asians, HLA-DR7 haplotypes protect from jSLE development.</p></list-item><list-item id="u0025"><label>&#x02022;</label><p id="p0025">In jSLE, low serum C4 levels may be the result of ancestral haplotypes.</p></list-item></list></p></abstract><kwd-group id="kwrds0010"><title>Keywords</title><kwd>Lupus</kwd><kwd>Genetic</kwd><kwd>Juvenile-onset</kwd><kwd>SLE</kwd><kwd>HLA</kwd><kwd>Haplotype</kwd><kwd>Disease activity</kwd><kwd>Complement</kwd><kwd>C4</kwd></kwd-group></article-meta></front><body><sec id="sec1"><label>1</label><title>Introduction</title><p id="p0035">Systemic lupus erythematosus (SLE) is a systemic autoimmune/inflammatory disease with a strong genetic component [<xref rid="bib1" ref-type="bibr">1</xref>,<xref rid="bib2" ref-type="bibr">2</xref>]. Approximately 15&#x02013;20&#x000a0;% of SLE patients develop disease prior to their 18th birthday. Disease onset during childhood and/or adolescence, when compared to patients with adult-onset SLE, associates with more severe clinical phenotypes, the need for more aggressive treatment, and less favorable outcomes [<xref rid="bib3" ref-type="bibr">3</xref>,<xref rid="bib4" ref-type="bibr">4</xref>]. Furthermore, across all age groups, SLE is more common and severe in people of non-European ancestry [<xref rid="bib1" ref-type="bibr">1</xref>,<xref rid="bib5" ref-type="bibr">[5]</xref>, <xref rid="bib6" ref-type="bibr">[6]</xref>, <xref rid="bib7" ref-type="bibr">[7]</xref>]. Because jSLE frequently affects multiple organ systems within an individual patient and its significant overlap with other autoimmune/inflammatory diseases (such as idiopathic arthritis, scleroderma, Sjogren's syndrome, etc.), it is a prime example for the concept of &#x0201c;poly-autoimmunity&#x0201d;, the presence of more than one well-defined autoimmune disease in a single patient [<xref rid="bib8" ref-type="bibr">8</xref>,<xref rid="bib9" ref-type="bibr">9</xref>]. Thus, understanding SLE may contribute to a better understanding also of these associated autoimmune/inflammatory diseases.</p><p id="p0040">A combination of pathomechanistic factors contribute to the development of SLE, including genetic and epigenetic alterations, immune dysfunction, and environmental impact [<xref rid="bib2" ref-type="bibr">2</xref>,<xref rid="bib10" ref-type="bibr">10</xref>,<xref rid="bib11" ref-type="bibr">11</xref>]. However, the contribution of these factors varies between individual patients, ancestries and age groups. Early disease onset and associated clinical severity have been attributed to an increased genetic burden in juvenile-onset (j)SLE when compared to patients with disease onset during adulthood [<xref rid="bib1" ref-type="bibr">1</xref>,<xref rid="bib7" ref-type="bibr">7</xref>,<xref rid="bib12" ref-type="bibr">12</xref>]. A relatively small proportion of SLE patients carry gene variants with high effect size that can cause &#x0201c;monogenic SLE&#x0201d; or SLE-like disease. Genes linked to &#x0201c;monogenic SLE&#x0201d; are most often involved in the classical complement pathway, Toll-like receptor/interferon signaling, and lymphocyte activation/function [<xref rid="bib7" ref-type="bibr">7</xref>,<xref rid="bib13" ref-type="bibr">13</xref>,<xref rid="bib14" ref-type="bibr">14</xref>]. The majority of SLE patients exhibit a combination of gene variants, so-called risk alleles, that increase the risk for disease development but are not &#x0201c;strong&#x0201d; enough <italic>per se</italic> to cause lupus [<xref rid="bib1" ref-type="bibr">1</xref>,<xref rid="bib2" ref-type="bibr">2</xref>,<xref rid="bib6" ref-type="bibr">6</xref>,<xref rid="bib7" ref-type="bibr">7</xref>,<xref rid="bib15" ref-type="bibr">15</xref>]. Among these risk alleles are variants affecting the four mega-base spanning <italic>Human Leukocyte Antigen</italic> (<italic>HLA</italic>) super-locus on chromosome 6p21.3 [<xref rid="bib16" ref-type="bibr">16</xref>]. The study of this highly variable region of the human genome is complicated by its gene density with 253 gene loci, including 132 coding genes, involved in innate and acquired immune responses, and the association of genes in conserved haplotypes [<xref rid="bib16" ref-type="bibr">16</xref>]. While early studies focused on highly polymorphic HLA class I and class II genes (including receptors that present peptides to CD8 [class I] or CD4 [class II] T cells), more recent analyses also considered associations with non-<italic>HLA</italic> genes within the cluster (e.g., complement <italic>C2</italic>, <italic>C4A</italic> and <italic>C4B</italic>) [<xref rid="bib17" ref-type="bibr">17</xref>]. Notably, in SLE, more <italic>HLA</italic> risk alleles are present when compared to other immune-mediated diseases [<xref rid="bib18" ref-type="bibr">18</xref>], but their analysis is complicated by inter-ancestral variation. For instance, HLA-DR2 (DRB1&#x02217;1501/DQB1&#x02217;0602) and -DR3 (DRB1&#x02217;0301/DQB1&#x02217;0201; MIM<ext-link ext-link-type="uri" xlink:href="https://omim.org/entry/142860?search=HLA-DR2&#x00026;highlight=%22hla%20dr2%22%2Chladr2" id="intref0010">&#x02217;142860</ext-link>) haplotypes that are associated with SLE in Caucasian but not in Asian or African ancestries [<xref rid="bib19" ref-type="bibr">19</xref>].</p><p id="p0045">Associations between SLE and genetic variation of the <italic>HLA</italic> cluster have almost exclusively been investigated in adult-onset SLE patients. This study, in contrast, has investigated a large multi-ancestral cohort of jSLE patients. A total of 309 jSLE patients enrolled in the UK JSLE Cohort Study and Repository were included. Diversity of HLA class I (A, B, C), class II (DRB1, DQA1, and DQB1) and class III (complement C2) clusters were analysed at the allele, protein, and extended haplotype level; variation was associated with clinical phenotypes.</p></sec><sec id="sec2"><label>2</label><title>Materials and methods</title><sec id="sec2.1"><label>2.1</label><title>Study cohort</title><p id="p0050">A total of 309 children and young people with SLE enrolled in the UK JSLE Cohort Study (<ext-link ext-link-type="uri" xlink:href="http://www.liv.ac.uk/ukjsle" id="intref0015">http://www.liv.ac.uk/ukjsle</ext-link>) were included in this study. Patients classified as having &#x0201c;monogenic SLE&#x0201d; and those with &#x0201c;mixed ancestry&#x0201d; were not included here [<xref rid="bib14" ref-type="bibr">14</xref>,<xref rid="bib15" ref-type="bibr">15</xref>,<xref rid="bib20" ref-type="bibr">20</xref>].</p><p id="p0055">The following clinical datasets were collected: (i) demographic information (age at disease onset, sex, ancestry: self-reported Caucasian, Asian, African/Caribbean descent; participants with mixed ancestry were excluded from this study); (ii) global disease activity scores, including the paediatric British Isles Lupus Assessment Grade 2004 (pBILAG-2004) and the SLE Disease Activity Index 2000 (SLEDAI-2K) score [<xref rid="bib21" ref-type="bibr">21</xref>,<xref rid="bib22" ref-type="bibr">22</xref>]; (iii) severity (using the numeric version of the pBILAG-2004 score: A&#x000a0;=&#x000a0;12, B&#x000a0;=&#x000a0;8, C&#x000a0;=&#x000a0;1, and D/E&#x000a0;=&#x000a0;0) of disease at the organ/system level [<xref rid="bib23" ref-type="bibr">23</xref>]; and (iv) SLE-associated laboratory parameters, including anti-double-stranded (ds)DNA antibodies, anti-extractable nuclear (ENA) antibodies, complement C3 and C4 levels, and white blood cell (WBC) count as previously described [<xref rid="bib24" ref-type="bibr">24</xref>,<xref rid="bib25" ref-type="bibr">25</xref>].</p><p id="p0060">Conducted in accordance with the declaration of Helsinki, the study received ethical approval from the National Research Ethics Service Northwest (REC 06/Q1502/77), and all participants and/or their legal guardians gave written informed patient assent/consent.</p></sec><sec id="sec2.2"><label>2.2</label><title>Sequencing and bioinformatic approach</title><p id="p0065">Sequence capture probes were designed to target <italic>HLA-A, HLA-B, HLA-C, HLA-DRA, HLA-DRB1, HLA-DQA1, HLA-DQB1, HLA-DQB2, HLA-DPA1, HLA-DPB1</italic> and <italic>C2</italic> gene loci. Sequencing libraries were prepared from genomic DNA, hybridized to the probes (NimbleGen/Roche, Basel, Switzerland) and sequenced with 150bp paired-end reads using Illumina MiSeq technology (Illumina, Inc., San Diego, USA). Demultiplexing, adaptor and quality trimming (Cutadapt v1.2.1, Sickle v1.2) of reads was performed [Cutadapt v1.2.1 (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.14806/ej.17.1.200" id="intref0020">https://doi.org/10.14806/ej.17.1.200</ext-link>), Sickle v1.2 (<ext-link ext-link-type="uri" xlink:href="https://github.com/najoshi/sickle" id="intref0025">https://github.com/najoshi/sickle</ext-link>)]. Trimmed reads were aligned to the human reference genome (GRCh38, including ALT alleles and decoy sequences) and processed with BWAkit (v0.7.15) (<ext-link ext-link-type="uri" xlink:href="https://doi.org/10.6084/M9.FIGSHARE.963153.V1" id="intref0031">https://doi.org/10.6084/M9.FIGSHARE.963153.V1</ext-link>), to genotype HLA alleles. The top matching allele, or allelic pairs in cases of heterozygosity, was identified and reported for each locus. Non-HLA sequencing data were aligned against the human reference genome (hg38) using BWA [<xref rid="bib26" ref-type="bibr">26</xref>], and variants were subsequently detected with <italic>Genome Analysis Toolkit Software</italic> (GATK) [<xref rid="bib26" ref-type="bibr">26</xref>,<xref rid="bib27" ref-type="bibr">27</xref>]. GATK base quality score recalibration was applied, variants were filtered using the GATK Variant Filtration tool and annotated using SnpEFF for the complement <italic>C2</italic> gene [<xref rid="bib28" ref-type="bibr">28</xref>].</p><p id="p0070">HLA allele frequencies at 2-field resolution in the UK (White British, n&#x000a0;=&#x000a0;475), Asia (n&#x000a0;=&#x000a0;6970), and Africa (n&#x000a0;=&#x000a0;4985) were obtained from the Allele Frequency Net Database (AFND, <ext-link ext-link-type="uri" xlink:href="http://www.allelefrequencies.net" id="intref0030">www.allelefrequencies.net</ext-link>) [<xref rid="bib29" ref-type="bibr">29</xref>], and the protein (P) designation was attributed to HLA sequences at 4-field resolution having the same antigen binding domain according to the HLA alleles nomenclature website (<ext-link ext-link-type="uri" xlink:href="https://hla.alleles.org" id="intref0035">https://hla.alleles.org</ext-link>) [<xref rid="bib30" ref-type="bibr">[30]</xref>, <xref rid="bib31" ref-type="bibr">[31]</xref>, <xref rid="bib32" ref-type="bibr">[32]</xref>].</p><p id="p0075">Minor allele frequencies (MAF) in UK controls (White British, n&#x000a0;=&#x000a0;276,338) were obtained from the UK blood bank database (<ext-link ext-link-type="uri" xlink:href="https://decaf.decode.com/" id="intref0040">https://decaf.decode.com/</ext-link>) [<xref rid="bib33" ref-type="bibr">33</xref>]; MAF in Asian (n&#x000a0;=&#x000a0;48,640) and African (n&#x000a0;=&#x000a0;15,100) controls were retrieved from the <italic>genome Aggregation Database</italic> (gnomAD) v2.1.1 (<ext-link ext-link-type="uri" xlink:href="https://gnomad.broadinstitute.org/" id="intref0045">https://gnomad.broadinstitute.org/</ext-link>) [<xref rid="bib34" ref-type="bibr">34</xref>].</p></sec><sec id="sec2.3"><label>2.3</label><title>Statistical analysis</title><p id="p0080">Quantitative data are presented as median&#x000a0;&#x000b1;&#x000a0;interquartile ranges (IQ) and analysed using ANOVA non-parametric tests with Dunn's test applied for post-hoc multiple comparisons in analysis of variance (ANOVA) when necessary. For categorical data, differences among groups were analysed using the Fisher's exact test. Principal component analysis (PCA) was performed to test ancestry associations between haplotypes using the ClustVis webtool (<ext-link ext-link-type="uri" xlink:href="http://biit.cs.ut.ee/clustvis/" id="intref0050">http://biit.cs.ut.ee/clustvis/</ext-link>) [<xref rid="bib35" ref-type="bibr">35</xref>]. For quantitative trait loci (QTL) analysis, Spearman's correlation test was performed using allele/protein/haplotype numbers (0, 1, and 2). The Benjamini-Hochberg False discovery rate p value (pFDR) was selected to control p-values for multiple testing, where appropriate. Results were visualised using PRISM10.3 (GraphPad Software, La Jolla, CA, USA).</p></sec></sec><sec id="sec3"><label>3</label><title>Results</title><sec id="sec3.1"><label>3.1</label><title>Cohort</title><p id="p0085">The majority of participants included in this study, 259/309 (83.8&#x000a0;%), were female. Three main ancestral groups were represented, Caucasians (n&#x000a0;=&#x000a0;151, 48.8&#x000a0;%) with a predominance of British origin (127/151, 80.1&#x000a0;%), Asians (n&#x000a0;=&#x000a0;108, 35.0&#x000a0;%), and participants of African/Caribbean ancestry (n&#x000a0;=&#x000a0;50, 16.2&#x000a0;%). When compared to Caucasians, minor demographic differences were observed in jSLE patients of Asian (sex distribition; <italic>p</italic>&#x000a0;=&#x000a0;0.03) or African/Caribbean ancestry (lower age at diagnosis/1st visit; lower global/mucocutaneous disease activity (0.003&#x0003c;<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.05) (<xref rid="tbl1" ref-type="table">Table 1</xref>). Minor differences in demographic and disease characteristics from this group to previous reports are primarily related to the exclusion of patients with &#x0201c;monogenic jSLE&#x0201d; [<xref rid="bib14" ref-type="bibr">14</xref>,<xref rid="bib15" ref-type="bibr">15</xref>,<xref rid="bib20" ref-type="bibr">20</xref>].<table-wrap position="float" id="tbl1"><label>Table 1</label><caption><p>Demographic and clinical characteristics.</p></caption><alt-text id="alttext0030">Table 1</alt-text><table frame="hsides" rules="groups"><thead><tr><th>Characteristics</th><th>Caucasians (n&#x000a0;=&#x000a0;151)</th><th>Asian ancestry (n&#x000a0;=&#x000a0;108)</th><th>African/Caribbean ancestry (n&#x000a0;=&#x000a0;50)</th><th>p values</th></tr></thead><tbody><tr><td align="left">Female: Male</td><td align="left">133:18</td><td align="left">82:26&#x02217;</td><td align="left">44:6</td><td align="char"><bold>0.027</bold></td></tr><tr><td align="left">Age at diagnosis (years)</td><td align="left">13.0 (10.7&#x02013;14.7)</td><td align="left">12.9 (10.6&#x02013;14.6)</td><td align="left">10.7 (8.9&#x02013;13.3)&#x02217;</td><td align="char"><bold>0.011</bold></td></tr><tr><td align="left">Age at 1st visit</td><td align="left">13 (11&#x02013;15)</td><td align="left">14 (11&#x02013;16)</td><td align="left">12.0 (9.2&#x02013;14.0)&#x02217;</td><td align="char"><bold>0.044</bold></td></tr><tr><td align="left">pBILAG-2004</td><td align="left">8 (3&#x02013;15)</td><td align="left">9 (4&#x02013;17)</td><td align="left">5 (1&#x02013;12)&#x02217;</td><td align="char"><bold>0.044</bold></td></tr><tr><td align="left">SLEDAI-2K</td><td align="left">10 (4&#x02013;17)</td><td align="left">8 (4&#x02013;14)</td><td align="left">5 (1&#x02013;12)&#x02217;</td><td align="char"><bold>0.003</bold></td></tr><tr><td align="left">Constitutional<sup>&#x00026;</sup></td><td align="left">0 (0&#x02013;8) [38&#x000a0;%]</td><td align="left">0 (0&#x02013;8) [47&#x000a0;%]</td><td align="left">0 (0&#x02013;3) [38&#x000a0;%]</td><td align="char">0.171</td></tr><tr><td align="left">Mucocutaneous<sup>&#x00026;</sup></td><td align="left">1 (0&#x02013;8) [62&#x000a0;%]</td><td align="left">1 (0&#x02013;8) [66&#x000a0;%]</td><td align="left">0 (0&#x02013;2.8) [36&#x000a0;%]&#x02217;</td><td align="char"><bold>0.002</bold></td></tr><tr><td align="left">Musculoskeletal<sup>&#x00026;</sup></td><td align="left">1 (0&#x02013;8) [60&#x000a0;%]</td><td align="left">1 (0&#x02013;1) [52&#x000a0;%]</td><td align="left">0 (0&#x02013;1) [44&#x000a0;%]</td><td align="char">0.057</td></tr><tr><td align="left">Haematological<sup>&#x00026;</sup></td><td align="left">1 (0&#x02013;8) [63&#x000a0;%]</td><td align="left">1 (0&#x02013;8) [63&#x000a0;%]</td><td align="left">1 (0&#x02013;8) [68&#x000a0;%]</td><td align="char">0.773</td></tr><tr><td align="left">Renal<sup>&#x00026;</sup></td><td align="left">0 (0&#x02013;8) [40&#x000a0;%]</td><td align="left">0 (0&#x02013;8) [36&#x000a0;%]</td><td align="left">0 (0&#x02013;8) [36&#x000a0;%]</td><td align="char">0.902</td></tr><tr><td align="left">Neurological<sup>&#x00026;</sup></td><td align="left">0 (0-0) [8&#x000a0;%]</td><td align="left">0 (0-0) [12&#x000a0;%]</td><td align="left">0 (0-0) [12&#x000a0;%]</td><td align="char">0.500</td></tr><tr><td align="left">Cardiorespiratory<sup>&#x00026;</sup></td><td align="left">0 (0-0) [15&#x000a0;%]</td><td align="left">0 (0-0) [11&#x000a0;%]</td><td align="left">0 (0-0) [6&#x000a0;%]</td><td align="char">0.230</td></tr><tr><td align="left">Gastrointestinal<sup>&#x00026;</sup></td><td align="left">0 (0-0) [7&#x000a0;%]</td><td align="left">0 (0-0) [9&#x000a0;%]</td><td align="left">0 (0-0) [4&#x000a0;%]</td><td align="char">0.475</td></tr><tr><td align="left">Ophthalmic<sup>&#x00026;</sup></td><td align="left">0 (0-0) [1&#x000a0;%]</td><td align="left">0 (0-0) [2&#x000a0;%]</td><td align="left">0 (0-0) [2&#x000a0;%]</td><td align="char">0.920</td></tr><tr><td align="left">Anti-dsDNA IgG, IU/mL [%, &#x0003c;10 IU/mL]</td><td align="left">37 (5&#x02013;196) [56&#x000a0;%]</td><td align="left">28 (7&#x02013;132) [56&#x000a0;%]</td><td align="left">38 (11&#x02013;141) [56&#x000a0;%]</td><td align="char">0.867</td></tr><tr><td align="left">C3 level, g/L [%, &#x0003c;0.88&#x000a0;g/L]</td><td align="left">0.94 (0.61&#x02013;1.22) [42&#x000a0;%]</td><td align="left">0.96 (0.58&#x02013;1.29) [42&#x000a0;%]</td><td align="left">0.92 (0.69&#x02013;1.15) [47&#x000a0;%]</td><td align="char">0.964</td></tr><tr><td align="left">C4 level, g/L [%, &#x0003c;0.16&#x000a0;g/L]</td><td align="left">0.11 (0.06&#x02013;19) [66&#x000a0;%]</td><td align="left">0.15 (0.08&#x02013;0.26) &#x02217; [51&#x000a0;%]</td><td align="left">0.08 (0.14&#x02013;0.2) [57&#x000a0;%]</td><td align="char">0.024</td></tr><tr><td align="left">WBC (10<sup>9</sup>/L)</td><td align="left">5.9 (4.0&#x02013;8.9)</td><td align="left">4.9 (4.0&#x02013;7.4)</td><td align="left">5.9 (4.1&#x02013;8.6)</td><td align="char">0.115</td></tr></tbody></table><table-wrap-foot><fn><p>A total of 309 participants with juvenile-onset systemic lupus erythematosus (jSLE) were included in this study. Presented are demographic and clinical features at their 1st study visit, stratified by ancestral group. Quantitative results are presented as median&#x000a0;&#x000b1;&#x000a0;first-third quartile. Significant Dunn's multiple comparison test factor (&#x02217;); pBILAG organ domain involvement (<sup>&#x00026;</sup>); pBILAG-2004 score: A&#x000a0;=&#x000a0;12, B&#x000a0;=&#x000a0;8, C&#x000a0;=&#x000a0;1, and D/E&#x000a0;=&#x000a0;0&#x000a0;(for each organ domain).</p></fn></table-wrap-foot></table-wrap></p></sec><sec id="sec3.2"><label>3.2</label><title>Multi-ethnic allele association analysis</title><p id="p0090">Using a high resolution 2-field approach for HLA class I/II, among all participants, a total of 20 HLA-A&#x02217;, 20 HLA-C&#x02217;, 24 HLA-B&#x02217;, 17 HLA-DRB1&#x02217;, 14 HLA-DQA1&#x02217;, and 15 HLADQB1&#x02217; alleles were identified at a frequency &#x0003e;1&#x000a0;%. Furthermore, there were 7 SNPs affecting the complement <italic>C2</italic> gene (Chr6: 31897847&#x02013;31944701, GRCh38) with a minor allele frequency (MAF)&#x000a0;&#x0003e;&#x000a0;1&#x000a0;%.</p><p id="p0095">Considering a pFDR&#x0003c;0.001 as a cutoff, we identified several ancestry differential SLE-associated haplotypes (h), including DR2h and DR3h, and protective alleles in HLA DR7h (<xref rid="fig1" ref-type="fig">Fig. 1</xref>):<list list-type="simple" id="ulist0015"><list-item id="u0030"><label>-</label><p id="p0100">HLA-DR2h associations included HLA-DRB1&#x02217;15:01 (African/Caribbean: OR&#x000a0;=&#x000a0;3.9, 95&#x000a0;% CI:2.0&#x02013;7.69, p&#x000a0;=&#x000a0;0.00099), HLA-DQA1&#x02217;01:02 (Asian: OR&#x000a0;=&#x000a0;1.86, 95&#x000a0;% CI:1.3&#x02013;2.6, p&#x000a0;=&#x000a0;0.0009), and HLA-DQB1&#x02217;06:02 (Africa/Caribbean: OR&#x000a0;=&#x000a0;2.25, 95&#x000a0;% CI:1.48&#x02013;3.4, p&#x000a0;=&#x000a0;0.0003).</p></list-item><list-item id="u0035"><label>-</label><p id="p0105">HLA-DR3h associations included HLA-B&#x02217;08:01 (Asian: OR&#x000a0;=&#x000a0;3.75, 95&#x000a0;% CI:2.25&#x02013;6.21, p&#x000a0;=&#x000a0;5&#x000a0;&#x000d7;&#x000a0;10<sup>&#x02212;6</sup>), and HLA-DRB1&#x02217;03:01 (Caucasian: OR&#x000a0;=&#x000a0;2.1, 95&#x000a0;% CI:1.46&#x02013;3.11, p&#x000a0;=&#x000a0;0.0001; and Asian: OR&#x000a0;=&#x000a0;2.5, 95&#x000a0;% CI:1.73&#x02013;3.5, p&#x000a0;=&#x000a0;2.7&#x000a0;&#x000d7;&#x000a0;10<sup>&#x02212;6</sup>).</p></list-item><list-item id="u0040"><label>-</label><p id="p0110">Protective associations in HLA-DR7h included HLA-DRB1&#x02217;07:01 (Asian: OR&#x000a0;=&#x000a0;0.44, 95&#x000a0;% CI:0.27&#x02013;0.72, p&#x000a0;=&#x000a0;0.0004) and HLA-DQA1&#x02217;02:01 (Asian: OR&#x000a0;=&#x000a0;0.34, 95&#x000a0;% CI:0.21&#x02013;0.56, p&#x000a0;=&#x000a0;1.8&#x000a0;&#x000d7;&#x000a0;10<sup>&#x02212;6</sup>).</p></list-item></list><fig id="fig1"><label>Fig. 1</label><caption><p><bold>Ancestry-differential HLA allele diversity in jSLE</bold>. A: Manhattan plot according to ancestral groups: Caucasians in blue, Asians in red, African/Caribbean descendants in green. Ancestry-related controls were obtained from several databases (Materials and Methods). HLA-class I, HLA-class III (C2 gene), and HLA-class II regions are represented on the horizontal axis with &#x02013; Log10 (p values) on the vertical axis. The statistical threshold was fixed at pFDR&#x000a0;=&#x000a0;0.001; and the p&#x000a0;=&#x000a0;0.01 cut-off is presented (doted lines). <bold>B-D:</bold> Odds ratios of HLA alleles significantly associated with jSLE across ethnicities. Significant risk and protective factors are displayed in colour (pFDR&#x0003c;0.001).</p></caption><alt-text id="alttext0010">Fig. 1</alt-text><graphic xlink:href="gr1"/></fig></p><p id="p0115">Additional, not previously reported risk associations were observed in jSLE patients of Asian descent, including HLA-C7&#x02217;07:02 (OR&#x000a0;=&#x000a0;2.7, 95&#x000a0;% CI:1.73&#x02013;3.39, p&#x000a0;=&#x000a0;2.7&#x000a0;&#x000d7;&#x000a0;10<sup>&#x02212;6</sup>), DRB1&#x02217;15:02 (OR&#x000a0;=&#x000a0;2.35, 95&#x000a0;% CI:1.57&#x02013;3.49, p&#x000a0;=&#x000a0;0.0001), and the <italic>C2</italic> rs9332730 splice variant (OR&#x000a0;=&#x000a0;2.23, 95&#x000a0;% CI:1.55&#x02013;3.19, p&#x000a0;=&#x000a0;9.3&#x000a0;&#x000d7;&#x000a0;10<sup>&#x02212;5</sup>). Further protective associations were retrieved for HLA-A&#x02217;33:03 (Asian: OR&#x000a0;=&#x000a0;0.21, 95&#x000a0;% CI:0.09&#x02013;0.51, p&#x000a0;=&#x000a0;2.8&#x000a0;&#x000d7;&#x000a0;10<sup>&#x02212;5</sup>), HLA-DQA1&#x02217;01:01 (Asia: OR&#x000a0;=&#x000a0;0.31, 95&#x000a0;% CI:0.14&#x02013;0.65, p&#x000a0;=&#x000a0;0.0005), HLA-DQA1&#x02217;03:01 (Caucasian: OR&#x000a0;=&#x000a0;0.28, 95&#x000a0;% CI:0.16&#x02013;0.46, p&#x000a0;=&#x000a0;3&#x000a0;&#x000d7;&#x000a0;10<sup>&#x02212;7</sup>; Asian: OR&#x000a0;=&#x000a0;0.35, 95&#x000a0;% IC: 0.18&#x02013;0.65, p&#x000a0;=&#x000a0;0.0003), and HLA-DQB1&#x02217;06:03 (Caucasian: OR&#x000a0;=&#x000a0;0.29, 95&#x000a0;% CI:0.15&#x02013;0.56, p&#x000a0;=&#x000a0;6&#x000a0;&#x000d7;&#x000a0;10<sup>&#x02212;5</sup>) (<xref rid="fig1" ref-type="fig">Fig. 1</xref>B and C &#x00026; D).</p><p id="p0120">Overall, 14 associations differentially affecting ancestries were reported across the <italic>HLA</italic> super-locus, which may result in part from distinct haplotype recombination (<xref rid="fig1" ref-type="fig">Fig. 1</xref>).</p></sec><sec id="sec3.3"><label>3.3</label><title>Ancestry-related haplotype diversity in jSLE</title><p id="p0125">To further characterize jSLE-associated HLA haplotypes across ancestries, unsupervised PCA was performed. Three haplotypes were mainly associated with jSLE in Caucasian participants: HLA-DR2h (HLA-DRB1&#x02217;15:01&#x0223c;DQA1&#x02217;01:02&#x0223c;DQB1&#x02217;06:02, affecting 33.8&#x000a0;%), HLA-DR3h (HLA-B&#x02217;08:02&#x0223c;DRB1&#x02217;03:01, affecting 30.4&#x000a0;%), and HLA-DR7h (HLA-DRB1&#x02217;07:01&#x0223c;DQA1&#x02217;02:01, affecting 19.2&#x000a0;%) (<xref rid="fig2" ref-type="fig">Fig. 2</xref>A).<fig id="fig2"><label>Fig. 2</label><caption><p><bold>HLA-DR2(h), -DR3h, and -DR7h haplotypes differentially associate with jSLE across ancestral groups. A-C</bold>: Principal component analysis (PCA) based on 14 risk/protective alleles identified in jSLE patients (<xref rid="fig1" ref-type="fig">Fig. 1</xref>) of Caucasian (<bold>A</bold>), Asian (<bold>B</bold>) or African/Caribbean ancestry (<bold>C</bold>). <bold>D:</bold> HLA-DR2h, <bold>E:</bold> HLA-DR3h and <bold>F:</bold> HLA-DR7h and other alleles according to the ancestry group.</p></caption><alt-text id="alttext0015">Fig. 2</alt-text><graphic xlink:href="gr2"/></fig></p><p id="p0130">Ancestral variation was observed for HLA-DR2h and HLA-DR3h (<xref rid="fig2" ref-type="fig">Fig. 2</xref>B&#x02013;F). Within the HLA-DR2h, HLA-DQA&#x02217;01:02 was associated with jSLE across ancestries, while weaker associations were seen for HLA-DQB1&#x02217;06:02 in Asian and HLA-DRB1&#x02217;15:01 in African/Caribbean patients (<xref rid="fig2" ref-type="fig">Fig. 2</xref>D). HLA-DRB1&#x02217;03:01 and HLA-DR3h were only recorded in jSLE patients of African/Caribbean ancestry (<xref rid="fig2" ref-type="fig">Fig. 2</xref>E). Alternative HLA-DR3h isoforms characterized Asian jSLE patients (HLA-C&#x02217;07:02&#x0223c;HLA-B&#x02217;08:02&#x0223c;rs9332730&#x0223c;DRB1&#x02217;03:01) that resulted from the integration of HLA-C&#x02217;07:02 (instead of HLA-C&#x02217;07:01 classically reported in the ancestral HLA-DR3h) and the presence of the <italic>C2</italic> rs9332730 splice variant.</p></sec><sec id="sec3.4"><label>3.4</label><title>HLA associations with clinical presentation</title><p id="p0135">Previous reports suggested genetic variation of the HLA-super locus to contribute to SLE pathophysiology and phenotypic diversity in adult-onset patients [<xref rid="bib36" ref-type="bibr">[36]</xref>, <xref rid="bib37" ref-type="bibr">[37]</xref>, <xref rid="bib38" ref-type="bibr">[38]</xref>]. To explore this hypothesis in jSLE, quantitative trait loci (QTL) analysis was conducted to test associations between clinical parameters and: i) the here identified 14 SLE-associated risk/protective HLA alleles, and HLA alleles with a population frequency &#x0003e;5&#x000a0;% (n&#x000a0;=&#x000a0;37); ii) resulting HLA proteins to explore effects mediated by disease driving epitopes (n&#x000a0;=&#x000a0;30); and iii) extended HLA haplotypes, including ancestral variants, to test for the presence of non-HLA allele risk factors in linkage disequilibrium (n&#x000a0;=&#x000a0;7).</p><p id="p0140">Using a Spearman's rho pFDR value of 0.001 as threshold, a negative correlation was identified between complement C4 protein levels and HLA-C&#x02217;07:01&#x000a0;at the allele level (p&#x000a0;=&#x000a0;0.001), and HLA-DR3h at the haplotype level (p&#x000a0;=&#x000a0;2.7&#x000a0;&#x000d7;&#x000a0;10<sup>&#x02212;5</sup>) (<xref rid="fig3" ref-type="fig">Fig. 3</xref>). This observation is in agreement with previous reports describing an over-representation of the <italic>C4B</italic> null allele, located in the HLA class III region, with the ancestral HLA-DR3h that includes HLA-C&#x02217;07:01 [<xref rid="bib39" ref-type="bibr">39</xref>]. Although the <italic>C4B</italic> gene was not included here, this hypothesis is strengthened by two arguments: i) we identified no direct involvement of HLA-DR3h corresponding HLA proteins HLA-C&#x02217;07:01P, HLA-B&#x02217;08:02P, and HLA-DRB1&#x02217;03:01P, and ii) the association between HLA-DR3h and C4 protein levels was limited to ancestral HLA-DR3h (X-B&#x02217;08:01-X-DRB1&#x02217;03:01) as compared to the HLA-DR3h variant associated with Asian ancestry (HLA-C&#x02217;07:02&#x0223c;HLA-B&#x02217;08:02&#x0223c;rs9332730&#x0223c;DRB1&#x02217;03:01). Moreover, an association between HLA-A&#x02217;03:01P, including HLA-A&#x02217;03:01 (03:01:01:01, and 03:01:27 but not 03:01:01:02N) and HLA-A&#x02217;03:20 alleles, and low white cell counts in jSLE was seen (p&#x000a0;=&#x000a0;0.0007); a lower significance was reported for the HLA-A&#x02217;03:01 allele (p&#x000a0;=&#x000a0;0.0015).<fig id="fig3"><label>Fig. 3</label><caption><p><bold><italic>jSLE-associated HLA quantitative trait loci (QTL). A:</italic></bold><italic>Manhattan plot of HLA alleles (x A&#x02217;, x C&#x02217;, B&#x02217;, x C2-factor B, x DRB1&#x02217;, x DQA1&#x02217;, and xDQB1&#x02217;) with a frequency &#x02265;0.05 and their association with age at diagnosis (years), disease activity (pBILAG 2004, SLEDAI-2K), disease activity (pBILAG 2004 organ domains), and clinical features.</italic><bold><italic>B:</italic></bold><italic>Concordance with HLA protein sequence.</italic><bold><italic>C:</italic></bold><italic>Concordance with haplotypes DR2(h), DR3h, DR7h and ancestral variants. On the y axis,&#x02013;Log10(p values) are presented, assessing concordance between allele/protein number (0, 1, and 2) or haplotype (DR3h/DR7h: 0, 2, 3, and 4 alleles; DR2h: 0, 2, 3, 4, 5, and 6 alleles), and the quantitative trait using the Spearman's correlation test. Alleles with at least one pFDR value&#x000a0;&#x02264;&#x000a0;0.001 are indicated as full circles and those with a least one p value 0.01&#x02264;p&#x000a0;&#x0003c;&#x000a0;0.001 are reported as an empty circles (A and B). Dark vertical lines represent p value thresholds at -LOG10&#x000a0;=&#x000a0;2 (p&#x000a0;=&#x000a0;0.01) and -LOG10&#x000a0;=&#x000a0;3 (p&#x000a0;=&#x000a0;0.001). C3: complement factor 3; C4: complement factor 4; anti-dsDNA: anti-double stranded DNA antibodies; anti-Sm: anti-Smith antibodies; anti-RNP: anti-ribonucleopeptide antibodies; Hb: hemoglobin; WBC: white blood cell count; Plt: platelet count; ESR: erythrocyte sedimentation rate.</italic></p></caption><alt-text id="alttext0020">Fig. 3</alt-text><graphic xlink:href="gr3"/></fig></p><p id="p0145">Finally, the ancestral DR3h (B&#x02217;08:01-X-DRB1&#x02217;03:01) exerts a dominant effect. QTL analysis was repeated and confirmed a negative correlation between HLA-DQA1&#x02217;01:02 (but not DR2h) and C4 protein level after ancestral DR3h was excluded from the analysis (p&#x000a0;=&#x000a0;0.0006) (<xref rid="fig4" ref-type="fig">Fig. 4</xref>).<fig id="fig4"><label>Fig. 4</label><caption><p><bold>jSLE-associated HLA quantitative trait loci after excluding individuals harboring the ancestral DR3 haplotype (B&#x02217;08:01-X-DRB1&#x02217;03:01). A</bold>: Manhattan plot of HLA alleles (x A&#x02217;, x C&#x02217;, B&#x02217;, x C2-factor B, x DRB1&#x02217;, x DQA1&#x02217;, and xDQB1&#x02217;) and their association with jSLE features. <bold>B:</bold> Concordance with HLA protein sequence. <bold>C:</bold> Concordance with haplotypes HLA-DR2, -DR3, -DR7 and ancestral variants. On the x axis, &#x02013;Log10(p values) are presented, assessing the concordance between allele/protein number (0, 1, and 2) or haplotype (HLA-DR3/DR7h: 0, 2, 3, and 4 alleles; HLA-DR2h: 0, 2, 3, 4, 5, and 6 alleles) and quantitative traits using the Spearman's correlation test. Alleles with at least one pFDR value&#x000a0;&#x02264;&#x000a0;0.001 are indicated as full circles and those with a least one p value 0.01&#x02264;p&#x000a0;&#x0003c;&#x000a0;0.001 are reported as an empty circles (A, B). Dark vertical lines represent p value thresholds at -LOG10&#x000a0;=&#x000a0;2 (p&#x000a0;=&#x000a0;0.01) and -LOG10&#x000a0;=&#x000a0;3 (p&#x000a0;=&#x000a0;0.001). C3: complement factor 3; C4: complement factor 4; anti-dsDNA: anti-double stranded DNA antibodies; anti-Sm: anti-Smith antibodies; anti-RNP: anti-ribonucleopeptide antibodies; Hb: hemoglobin; WBC: white blood cell count; Plt: platelet count; ESR: erythrocyte sedimentation rate.</p></caption><alt-text id="alttext0025">Fig. 4</alt-text><graphic xlink:href="gr4"/></fig></p></sec></sec><sec id="sec4"><label>4</label><title>Discussion</title><p id="p0150">This study provides the first comprehensive mapping exercise of the HLA super-locus in jSLE across ancestral groups. It confirms previous observation in adult-onset SLE cohorts reporting prominent roles for DR2h and DR3h as risk factors. This underscores the importance of HLA super locus variation in the pathophysiology of SLE, including juvenile-onset disease. It also emphasizes the importance of ancestry-linked genetic diversity and its contribution to differential disease presentation and outcomes, especially affecting HLA-DR2h, -DR3h (associated SLE risk) and -DR7h (protective).</p><p id="p0155">Associations between HLA-DR2h and disease risk has previously been reported in adult-SLE cohorts [<xref rid="bib40" ref-type="bibr">40</xref>], and two possible mechanisms have been suggested. One relates to the presence of SLE-associated SNPs in strong linkage disequilibrium with HLA-DRB1&#x02217;15:01 present in the intergenic <italic>XL9</italic> region, located between HLA-DRB1 and HLA-DQA1, resulting in increased surface expression of these genes in HLA-DR2h carriers [<xref rid="bib41" ref-type="bibr">41</xref>,<xref rid="bib42" ref-type="bibr">42</xref>]. The second hypothesis, limited to HLA-DRB1&#x02217;15:01 in Asians, links a low copy number of the <italic>C4A</italic> gene with DR2h [<xref rid="bib43" ref-type="bibr">43</xref>,<xref rid="bib44" ref-type="bibr">44</xref>] (below). This would also explain the herein reported association between the DR2h-associated jSLE factor HLA-DQA1&#x02217;01:02 and a low C4 levels in Asian participants (after excluding DR3h). Across ancestral groups in this jSLE cohort, HLA-DQA&#x02217;01:02 was the most conserved DR2h-risk factor when comparing Caucasian (HLA-DRB1&#x02217;15:01&#x0223c;DQA&#x02217;01:02&#x0223c;DQB1&#x02217;06:02), Asian (HLA-DRB1&#x02217;15:01&#x0223c;DQA&#x02217;01:02&#x0223c;X), and African/Caribbean (X&#x000a0;&#x0223c;&#x000a0;DQA&#x02217;01:02&#x0223c;DQB1&#x02217;06:02) sub-cohorts.</p><p id="p0160">In line with the identified negative association between DR7h and SLE in Asian participants in the current study, a protective role of DR7h in SLE has also previously been reported [<xref rid="bib45" ref-type="bibr">45</xref>,<xref rid="bib46" ref-type="bibr">46</xref>]. While associations between clinical phenotypes in DR7h were not seen in this cohort, others reported associations with predominantly cutaneous presentation [<xref rid="bib46" ref-type="bibr">46</xref>,<xref rid="bib47" ref-type="bibr">47</xref>], and specific autoantibody patterns including anti-Smith (Sm), anti-SSA/Ro, and anti-cardiolipin autoantibody positivity in adult-onset SLE cohorts [<xref rid="bib48" ref-type="bibr">[48]</xref>, <xref rid="bib49" ref-type="bibr">[49]</xref>, <xref rid="bib50" ref-type="bibr">[50]</xref>]. Differences may be partially linked to the more severe phenotypes observed in juvenile-when compared to adult-onset SLE [<xref rid="bib1" ref-type="bibr">1</xref>,<xref rid="bib4" ref-type="bibr">4</xref>,<xref rid="bib7" ref-type="bibr">7</xref>].</p><p id="p0165">Associations between HLA variation and clinical characteristics exist and are complex, involving <italic>HLA</italic> alleles (HLA-DQA1&#x02217;01:02 and low C4 levels), HLA proteins (HLA-A&#x02217;03:01P and low white blood cell count), and the ancestral DR3h (with low C4 levels).</p><p id="p0170">In jSLE, low C4 protein levels may either be the result of genetic factors or the consumption of the classical complement pathway (also associated with low C3) [<xref rid="bib51" ref-type="bibr">51</xref>]. The link between a homozygous C4 deficiency affecting both <italic>C4A</italic> and <italic>C4B</italic> genes at the <italic>HLA</italic> class III region is extremely rare, unlike the presence of a <italic>C4B</italic> null allele leading to partial C4 deficiency previously reported in Caucasian adult-onset SLE patients carrying DR3h [<xref rid="bib52" ref-type="bibr">52</xref>]. Furthermore, linkage disequilibrium between the <italic>C4B</italic> null allele (prevalence: 45&#x02013;66&#x000a0;%) and DR3h (prevalence: 22&#x02013;29&#x000a0;%) is partial in this ancestral group [<xref rid="bib39" ref-type="bibr">39</xref>]. When <italic>C4B</italic> is duplicated, it associates with the presence of the minor allele <italic>C2</italic> SNP rs9332730-C [<xref rid="bib53" ref-type="bibr">53</xref>]. The presence of rs9332730-C in the alternative Asian DR3h supports <italic>C4B</italic> gene duplication, which may explain normal C4 levels associated with the alternative DR3h. However, in the current study, we could not exclude underlying mechanisms other than C4, as both ancestral and Asian alternative DR3h were identified as risk factors for jSLE. Lastly, the recent identification of an epitope encoded HLA-DRB1&#x02217;03:01 that requires interferon-gamma to be functional suggests additional pathomechanisms, independent from antigen presentation to be involved in haplotype:phenotype associations [<xref rid="bib38" ref-type="bibr">38</xref>].</p><p id="p0175">The association between HLA-A&#x02217;03:01P, and to a lower extent also for HLA-A&#x02217;03:01, and low white cell counts points to a potential direct effect, that needs to be confirmed. The HLA-A&#x02217;03:01P allele has previously been associated with other immune-mediated diseases such as multiple sclerosis (MS) and type 1 diabetes [<xref rid="bib54" ref-type="bibr">54</xref>,<xref rid="bib55" ref-type="bibr">55</xref>]. In humanized mice, HLA-A&#x02217;03:01P contributes to the induction of MS after immunization with the myelin proteolipid protein-derived PLP45&#x02013;53 peptide (KLIETYFSK) [<xref rid="bib56" ref-type="bibr">56</xref>].</p><p id="p0180">While this study provides the most comprehensive HLA study in jSLE to date, it has several limitations. Though a national cohort from the UK, the study population was relatively small, especially when considering individual ancestral groups. While here, SLE risk was tested at the &#x0201c;continental&#x0201d; ancestry level and compared to publicly available datasets, larger international cohorts may allow testing at &#x0201c;country level&#x0201d; which may allow for validation of minor associations and better characterization of SLE-associated haplotypes. With the notable exception of the <italic>C2</italic> region, non-HLA genes were not considered in the extended haplotype characterization, which may introduce a bias, as revealed with <italic>C2</italic> rs9332730 to differentiate Caucasian from Asian HLA-DR3h. Lastly, because of incomplete sequencing data, the <italic>C4A</italic> and <italic>C4B</italic> genes have not been included in this study. Thus, we cannot completely exclude that the association with C4 deficiency may result from activation of the classical complement pathway. However, this risk is limited as no association with low C3 levels was found.</p><p id="p0185">In conclusion, this study underscores the importance of HLA variation as a risk factor in SLE, including jSLE. It promises potential for future patient stratification and risk assessment based on genetic profiling and underscores the importance of considering inter-ancestral differences in genetic composition and associated disease risk. Because jSLE frequently presents with &#x0201c;poly-autoimmunity&#x0201d;, findings from this study may also inform associated autoimmune/inflammatory diseases.</p></sec><sec id="sec5"><title>CRediT authorship contribution statement</title><p id="p0190"><bold>Yves Renaudineau:</bold> Writing &#x02013; review &#x00026; editing, Writing &#x02013; original draft, Visualization, Validation, Supervision, Software, Resources, Methodology, Investigation, Formal analysis, Data curation. <bold>Amandine Charras:</bold> Writing &#x02013; review &#x00026; editing, Writing &#x02013; original draft, Supervision, Software, Resources, Project administration, Methodology, Investigation, Formal analysis, Data curation. <bold>Valentina Natoli:</bold> Writing &#x02013; review &#x00026; editing, Validation, Resources, Project administration, Methodology, Investigation, Formal analysis, Data curation. <bold>Nicolas Congy-Jolivet:</bold> Writing &#x02013; review &#x00026; editing, Software, Methodology, Investigation, Formal analysis. <bold>Sam Haldenby:</bold> Writing &#x02013; review &#x00026; editing, Methodology, Investigation, Formal analysis, Data curation. <bold>Xuan Liu:</bold> Writing &#x02013; review &#x00026; editing, Methodology, Investigation, Formal analysis, Data curation. <bold>Yongxiang Fang:</bold> Writing &#x02013; review &#x00026; editing, Methodology, Investigation, Formal analysis, Data curation. <bold>Eve MD. Smith:</bold> Writing &#x02013; review &#x00026; editing, Resources, Methodology, Investigation, Data curation. <bold>Michael W. Beresford:</bold> Writing &#x02013; review &#x00026; editing, Resources, Project administration, Funding acquisition, Data curation, Conceptualization. <bold>Christian M. Hedrich:</bold> Writing &#x02013; review &#x00026; editing, Writing &#x02013; original draft, Visualization, Validation, Supervision, Software, Resources, Project administration, Methodology, Investigation, Funding acquisition, Formal analysis, Data curation, Conceptualization.</p></sec><sec sec-type="COI-statement" id="coi0010"><title>Declaration of competing interest</title><p id="p0195">The authors report no conflict of interest.</p></sec></body><back><ref-list id="cebib0010"><title>References</title><ref id="bib1"><label>1</label><element-citation publication-type="journal" id="sref1"><person-group person-group-type="author"><name><surname>Charras</surname><given-names>A.</given-names></name><name><surname>Smith</surname><given-names>E.</given-names></name><name><surname>Hedrich</surname><given-names>C.M.</given-names></name></person-group><article-title>Systemic lupus erythematosus in children and young people</article-title><source>Curr. Rheumatol. Rep.</source><volume>23</volume><issue>3</issue><year>2021</year><fpage>20</fpage><pub-id pub-id-type="pmid">33569643</pub-id>
</element-citation></ref><ref id="bib2"><label>2</label><element-citation publication-type="journal" id="sref2"><person-group person-group-type="author"><name><surname>Tsokos</surname><given-names>G.C.</given-names></name></person-group><article-title>The immunology of systemic lupus erythematosus</article-title><source>Nat. Immunol.</source><volume>25</volume><issue>8</issue><year>2024</year><fpage>1332</fpage><lpage>1343</lpage><pub-id pub-id-type="pmid">39009839</pub-id>
</element-citation></ref><ref id="bib3"><label>3</label><element-citation publication-type="journal" id="sref3"><person-group person-group-type="author"><name><surname>Massias</surname><given-names>J.S.</given-names></name><name><surname>Smith</surname><given-names>E.M.D.</given-names></name><name><surname>Al-Abadi</surname><given-names>E.</given-names></name><name><surname>Armon</surname><given-names>K.</given-names></name><name><surname>Bailey</surname><given-names>K.</given-names></name><name><surname>Ciurtin</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Clinical and laboratory characteristics in juvenile-onset systemic lupus erythematosus across age groups</article-title><source>Lupus</source><volume>29</volume><issue>5</issue><year>2020</year><fpage>474</fpage><lpage>481</lpage><pub-id pub-id-type="pmid">32233733</pub-id>
</element-citation></ref><ref id="bib4"><label>4</label><element-citation publication-type="journal" id="sref4"><person-group person-group-type="author"><name><surname>Ambrose</surname><given-names>N.</given-names></name><name><surname>Morgan</surname><given-names>T.A.</given-names></name><name><surname>Galloway</surname><given-names>J.</given-names></name><name><surname>Ionnoau</surname><given-names>Y.</given-names></name><name><surname>Beresford</surname><given-names>M.W.</given-names></name><name><surname>Isenberg</surname><given-names>D.A.</given-names></name><etal/></person-group><article-title>Differences in disease phenotype and severity in SLE across age groups</article-title><source>Lupus</source><volume>25</volume><issue>14</issue><year>2016</year><fpage>1542</fpage><lpage>1550</lpage><pub-id pub-id-type="pmid">27147622</pub-id>
</element-citation></ref><ref id="bib5"><label>5</label><element-citation publication-type="journal" id="sref5"><person-group person-group-type="author"><name><surname>Massias</surname><given-names>J.S.</given-names></name><name><surname>Smith</surname><given-names>E.M.</given-names></name><name><surname>Al-Abadi</surname><given-names>E.</given-names></name><name><surname>Armon</surname><given-names>K.</given-names></name><name><surname>Bailey</surname><given-names>K.</given-names></name><name><surname>Ciurtin</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Clinical and laboratory phenotypes in juvenile-onset Systemic Lupus Erythematosus across ethnicities in the UK</article-title><source>Lupus</source><volume>30</volume><issue>4</issue><year>2021</year><fpage>597</fpage><lpage>607</lpage><pub-id pub-id-type="pmid">33413005</pub-id>
</element-citation></ref><ref id="bib6"><label>6</label><element-citation publication-type="journal" id="sref6"><person-group person-group-type="author"><name><surname>Tsokos</surname><given-names>G.C.</given-names></name></person-group><article-title>Systemic lupus erythematosus</article-title><source>N. Engl. J. Med.</source><volume>365</volume><issue>22</issue><year>2011</year><fpage>2110</fpage><lpage>2121</lpage><pub-id pub-id-type="pmid">22129255</pub-id>
</element-citation></ref><ref id="bib7"><label>7</label><element-citation publication-type="journal" id="sref7"><person-group person-group-type="author"><name><surname>Hedrich</surname><given-names>C.M.</given-names></name><name><surname>Smith</surname><given-names>E.M.D.</given-names></name><name><surname>Beresford</surname><given-names>M.W.</given-names></name></person-group><article-title>Juvenile-onset systemic lupus erythematosus (jSLE) - pathophysiological concepts and treatment options</article-title><source>Best Pract. Res. Clin. Rheumatol.</source><volume>31</volume><issue>4</issue><year>2017</year><fpage>488</fpage><lpage>504</lpage><pub-id pub-id-type="pmid">29773269</pub-id>
</element-citation></ref><ref id="bib8"><label>8</label><element-citation publication-type="journal" id="sref8"><person-group person-group-type="author"><name><surname>Malagon</surname><given-names>C.</given-names></name><name><surname>Gomez</surname><given-names>M.D.P.</given-names></name><name><surname>Mosquera</surname><given-names>C.</given-names></name><name><surname>Vargas</surname><given-names>C.</given-names></name><name><surname>Gonzalez</surname><given-names>T.</given-names></name><name><surname>Arango</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Juvenile polyautoimmunity in a rheumatology setting</article-title><source>Autoimmun. Rev.</source><volume>18</volume><issue>4</issue><year>2019</year><fpage>369</fpage><lpage>381</lpage><pub-id pub-id-type="pmid">30772494</pub-id>
</element-citation></ref><ref id="bib9"><label>9</label><element-citation publication-type="journal" id="sref9"><person-group person-group-type="author"><name><surname>Rojas</surname><given-names>M.</given-names></name><name><surname>Ramirez-Santana</surname><given-names>C.</given-names></name><name><surname>Acosta-Ampudia</surname><given-names>Y.</given-names></name><name><surname>Monsalve</surname><given-names>D.M.</given-names></name><name><surname>Rodriguez-Jimenez</surname><given-names>M.</given-names></name><name><surname>Zapata</surname><given-names>E.</given-names></name><etal/></person-group><article-title>New insights into the taxonomy of autoimmune diseases based on polyautoimmunity</article-title><source>J. Autoimmun.</source><volume>126</volume><year>2022</year><object-id pub-id-type="publisher-id">102780</object-id></element-citation></ref><ref id="bib10"><label>10</label><element-citation publication-type="journal" id="sref10"><person-group person-group-type="author"><name><surname>Brooks</surname><given-names>W.H.</given-names></name><name><surname>Le Dantec</surname><given-names>C.</given-names></name><name><surname>Pers</surname><given-names>J.O.</given-names></name><name><surname>Youinou</surname><given-names>P.</given-names></name><name><surname>Renaudineau</surname><given-names>Y.</given-names></name></person-group><article-title>Epigenetics and autoimmunity</article-title><source>J. Autoimmun.</source><volume>34</volume><issue>3</issue><year>2010</year><fpage>J207</fpage><lpage>J219</lpage><pub-id pub-id-type="pmid">20053532</pub-id>
</element-citation></ref><ref id="bib11"><label>11</label><element-citation publication-type="journal" id="sref11"><person-group person-group-type="author"><name><surname>Hedrich</surname><given-names>C.M.</given-names></name><name><surname>Tsokos</surname><given-names>G.C.</given-names></name></person-group><article-title>Epigenetic mechanisms in systemic lupus erythematosus and other autoimmune diseases</article-title><source>Trends Mol. Med.</source><volume>17</volume><issue>12</issue><year>2011</year><fpage>714</fpage><lpage>724</lpage><pub-id pub-id-type="pmid">21885342</pub-id>
</element-citation></ref><ref id="bib12"><label>12</label><element-citation publication-type="journal" id="sref12"><person-group person-group-type="author"><name><surname>Webb</surname><given-names>R.</given-names></name><name><surname>Kelly</surname><given-names>J.A.</given-names></name><name><surname>Somers</surname><given-names>E.C.</given-names></name><name><surname>Hughes</surname><given-names>T.</given-names></name><name><surname>Kaufman</surname><given-names>K.M.</given-names></name><name><surname>Sanchez</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Early disease onset is predicted by a higher genetic risk for lupus and is associated with a more severe phenotype in lupus patients</article-title><source>Ann. Rheum. Dis.</source><volume>70</volume><issue>1</issue><year>2011</year><fpage>151</fpage><lpage>156</lpage><pub-id pub-id-type="pmid">20881011</pub-id>
</element-citation></ref><ref id="bib13"><label>13</label><element-citation publication-type="journal" id="sref13"><person-group person-group-type="author"><name><surname>Alperin</surname><given-names>J.M.</given-names></name><name><surname>Ortiz-Fernandez</surname><given-names>L.</given-names></name><name><surname>Sawalha</surname><given-names>A.H.</given-names></name></person-group><article-title>Monogenic lupus: a developing paradigm of disease</article-title><source>Front. Immunol.</source><volume>9</volume><year>2018</year><fpage>2496</fpage><pub-id pub-id-type="pmid">30459768</pub-id>
</element-citation></ref><ref id="bib14"><label>14</label><element-citation publication-type="journal" id="sref14"><person-group person-group-type="author"><name><surname>Charras</surname><given-names>A.</given-names></name><name><surname>Haldenby</surname><given-names>S.</given-names></name><name><surname>Smith</surname><given-names>E.M.D.</given-names></name><name><surname>Egbivwie</surname><given-names>N.</given-names></name><name><surname>Olohan</surname><given-names>L.</given-names></name><name><surname>Kenny</surname><given-names>J.G.</given-names></name><etal/></person-group><article-title>Panel sequencing links rare, likely damaging gene variants with distinct clinical phenotypes and outcomes in juvenile-onset SLE</article-title><source>Rheumatology</source><volume>62</volume><issue>SI2</issue><year>2023</year><fpage>SI210</fpage><lpage>S225</lpage><pub-id pub-id-type="pmid">35532072</pub-id>
</element-citation></ref><ref id="bib15"><label>15</label><element-citation publication-type="journal" id="sref15"><person-group person-group-type="author"><name><surname>Renaudineau</surname><given-names>Y.</given-names></name><name><surname>Charras</surname><given-names>A.</given-names></name><name><surname>Natoli</surname><given-names>V.</given-names></name><name><surname>Fusaro</surname><given-names>M.</given-names></name><name><surname>Smith</surname><given-names>E.M.D.</given-names></name><name><surname>Beresford</surname><given-names>M.W.</given-names></name><etal/></person-group><article-title>Type I interferon associated epistasis may contribute to early disease-onset and high disease activity in juvenile-onset</article-title><source>lupus. Clin Immunol.</source><volume>262</volume><year>2024</year><object-id pub-id-type="publisher-id">110194</object-id></element-citation></ref><ref id="bib16"><label>16</label><element-citation publication-type="journal" id="sref16"><person-group person-group-type="author"><name><surname>Shiina</surname><given-names>T.</given-names></name><name><surname>Hosomichi</surname><given-names>K.</given-names></name><name><surname>Inoko</surname><given-names>H.</given-names></name><name><surname>Kulski</surname><given-names>J.K.</given-names></name></person-group><article-title>The HLA genomic loci map: expression, interaction, diversity and disease</article-title><source>J. Hum. Genet.</source><volume>54</volume><issue>1</issue><year>2009</year><fpage>15</fpage><lpage>39</lpage><pub-id pub-id-type="pmid">19158813</pub-id>
</element-citation></ref><ref id="bib17"><label>17</label><element-citation publication-type="journal" id="sref17"><person-group person-group-type="author"><name><surname>Hachiya</surname><given-names>Y.</given-names></name><name><surname>Kawasaki</surname><given-names>A.</given-names></name><name><surname>Oka</surname><given-names>S.</given-names></name><name><surname>Kondo</surname><given-names>Y.</given-names></name><name><surname>Ito</surname><given-names>S.</given-names></name><name><surname>Matsumoto</surname><given-names>I.</given-names></name><etal/></person-group><article-title>Association of HLA-G 3' untranslated region polymorphisms with systemic lupus erythematosus in a Japanese population: a case-control association study</article-title><source>PLoS One</source><volume>11</volume><issue>6</issue><year>2016</year><object-id pub-id-type="publisher-id">e0158065</object-id></element-citation></ref><ref id="bib18"><label>18</label><element-citation publication-type="journal" id="sref18"><person-group person-group-type="author"><name><surname>Butler-Laporte</surname><given-names>G.</given-names></name><name><surname>Farjoun</surname><given-names>J.</given-names></name><name><surname>Nakanishi</surname><given-names>T.</given-names></name><name><surname>Lu</surname><given-names>T.</given-names></name><name><surname>Abner</surname><given-names>E.</given-names></name><name><surname>Chen</surname><given-names>Y.</given-names></name><etal/></person-group><article-title>HLA allele-calling using multi-ancestry whole-exome sequencing from the UK Biobank identifies 129 novel associations in 11 autoimmune diseases</article-title><source>Commun. Biol.</source><volume>6</volume><issue>1</issue><year>2023</year><fpage>1113</fpage><pub-id pub-id-type="pmid">37923823</pub-id>
</element-citation></ref><ref id="bib19"><label>19</label><element-citation publication-type="journal" id="sref19"><person-group person-group-type="author"><name><surname>Morris</surname><given-names>D.L.</given-names></name><name><surname>Taylor</surname><given-names>K.E.</given-names></name><name><surname>Fernando</surname><given-names>M.M.</given-names></name><name><surname>Nititham</surname><given-names>J.</given-names></name><name><surname>Alarcon-Riquelme</surname><given-names>M.E.</given-names></name><name><surname>Barcellos</surname><given-names>L.F.</given-names></name><etal/></person-group><article-title>Unraveling multiple MHC gene associations with systemic lupus erythematosus: model choice indicates a role for HLA alleles and non-HLA genes in Europeans</article-title><source>Am. J. Hum. Genet.</source><volume>91</volume><issue>5</issue><year>2012</year><fpage>778</fpage><lpage>793</lpage><pub-id pub-id-type="pmid">23084292</pub-id>
</element-citation></ref><ref id="bib20"><label>20</label><element-citation publication-type="journal" id="sref20"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>E.M.D.</given-names></name><name><surname>Egbivwie</surname><given-names>N.</given-names></name><name><surname>Jorgensen</surname><given-names>A.L.</given-names></name><name><surname>Ciurtin</surname><given-names>C.</given-names></name><name><surname>Al-Abadi</surname><given-names>E.</given-names></name><name><surname>Armon</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Real world treatment of juvenile-onset systemic lupus erythematosus: data from the UK JSLE cohort study</article-title><source>Clin. Immunol.</source><volume>239</volume><year>2022</year><object-id pub-id-type="publisher-id">109028</object-id></element-citation></ref><ref id="bib21"><label>21</label><element-citation publication-type="journal" id="sref21"><person-group person-group-type="author"><name><surname>Marks</surname><given-names>S.D.</given-names></name><name><surname>Pilkington</surname><given-names>C.</given-names></name><name><surname>Woo</surname><given-names>P.</given-names></name><name><surname>Dillon</surname><given-names>M.J.</given-names></name></person-group><article-title>The use of the British Isles Lupus Assessment Group (BILAG) index as a valid tool in assessing disease activity in childhood-onset systemic lupus erythematosus</article-title><source>Rheumatology</source><volume>43</volume><issue>9</issue><year>2004</year><fpage>1186</fpage><lpage>1189</lpage><pub-id pub-id-type="pmid">15226518</pub-id>
</element-citation></ref><ref id="bib22"><label>22</label><element-citation publication-type="journal" id="sref22"><person-group person-group-type="author"><name><surname>Gladman</surname><given-names>D.D.</given-names></name><name><surname>Ibanez</surname><given-names>D.</given-names></name><name><surname>Urowitz</surname><given-names>M.B.</given-names></name></person-group><article-title>Systemic lupus erythematosus disease activity index 2000</article-title><source>J. Rheumatol.</source><volume>29</volume><issue>2</issue><year>2002</year><fpage>288</fpage><lpage>291</lpage><pub-id pub-id-type="pmid">11838846</pub-id>
</element-citation></ref><ref id="bib23"><label>23</label><element-citation publication-type="journal" id="sref23"><person-group person-group-type="author"><name><surname>Yee</surname><given-names>C.S.</given-names></name><name><surname>Cresswell</surname><given-names>L.</given-names></name><name><surname>Farewell</surname><given-names>V.</given-names></name><name><surname>Rahman</surname><given-names>A.</given-names></name><name><surname>Teh</surname><given-names>L.S.</given-names></name><name><surname>Griffiths</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Numerical scoring for the BILAG-2004 index</article-title><source>Rheumatology</source><volume>49</volume><issue>9</issue><year>2010</year><fpage>1665</fpage><lpage>1669</lpage><pub-id pub-id-type="pmid">20181671</pub-id>
</element-citation></ref><ref id="bib24"><label>24</label><element-citation publication-type="journal" id="sref24"><person-group person-group-type="author"><name><surname>Renaudineau</surname><given-names>Y.</given-names></name><name><surname>Chauveau</surname><given-names>D.</given-names></name><name><surname>Faguer</surname><given-names>S.</given-names></name><name><surname>Huart</surname><given-names>A.</given-names></name><name><surname>Ribes</surname><given-names>D.</given-names></name><name><surname>Pugnet</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Urinary soluble CD163 is useful as "liquid biopsy" marker in lupus nephritis at both diagnosis and follow-up to predict impending flares</article-title><source>J Transl Autoimmun.</source><volume>9</volume><year>2024</year><object-id pub-id-type="publisher-id">100244</object-id></element-citation></ref><ref id="bib25"><label>25</label><element-citation publication-type="journal" id="sref25"><person-group person-group-type="author"><name><surname>Carle</surname><given-names>C.</given-names></name><name><surname>Fortenfant</surname><given-names>F.</given-names></name><name><surname>Tauber</surname><given-names>M.</given-names></name><name><surname>Tournier</surname><given-names>E.</given-names></name><name><surname>Paul</surname><given-names>C.</given-names></name><name><surname>Bost</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Lupus band test can be used in combination with anti-chromatin antibodies and complement analysis to predict transition from cutaneous to systemic lupus</article-title><source>Clin. Immunol.</source><volume>234</volume><year>2022</year><object-id pub-id-type="publisher-id">108908</object-id></element-citation></ref><ref id="bib26"><label>26</label><element-citation publication-type="journal" id="sref26"><person-group person-group-type="author"><name><surname>Li</surname><given-names>H.</given-names></name><name><surname>Durbin</surname><given-names>R.</given-names></name></person-group><article-title>Fast and accurate short read alignment with Burrows-Wheeler transform</article-title><source>Bioinformatics</source><volume>25</volume><issue>14</issue><year>2009</year><fpage>1754</fpage><lpage>1760</lpage><pub-id pub-id-type="pmid">19451168</pub-id>
</element-citation></ref><ref id="bib27"><label>27</label><element-citation publication-type="journal" id="sref27"><person-group person-group-type="author"><name><surname>Van der Auwera</surname><given-names>G.A.</given-names></name><name><surname>Carneiro</surname><given-names>M.O.</given-names></name><name><surname>Hartl</surname><given-names>C.</given-names></name><name><surname>Poplin</surname><given-names>R.</given-names></name><name><surname>Del Angel</surname><given-names>G.</given-names></name><name><surname>Levy-Moonshine</surname><given-names>A.</given-names></name><etal/></person-group><article-title>From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline</article-title><source>Curr Protoc Bioinformatics</source><volume>43</volume><issue>1110</issue><year>2013</year><fpage>11</fpage><comment>0 1- 0 33</comment></element-citation></ref><ref id="bib28"><label>28</label><element-citation publication-type="journal" id="sref28"><person-group person-group-type="author"><name><surname>Cingolani</surname><given-names>P.</given-names></name><name><surname>Platts</surname><given-names>A.</given-names></name><name><surname>Wang le</surname><given-names>L.</given-names></name><name><surname>Coon</surname><given-names>M.</given-names></name><name><surname>Nguyen</surname><given-names>T.</given-names></name><name><surname>Wang</surname><given-names>L.</given-names></name><etal/></person-group><article-title>A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3</article-title><source>Fly</source><volume>6</volume><issue>2</issue><year>2012</year><fpage>80</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">22728672</pub-id>
</element-citation></ref><ref id="bib29"><label>29</label><element-citation publication-type="journal" id="sref29"><person-group person-group-type="author"><name><surname>Gonzalez-Galarza</surname><given-names>F.F.</given-names></name><name><surname>McCabe</surname><given-names>A.</given-names></name><name><surname>Santos</surname><given-names>E.</given-names></name><name><surname>Jones</surname><given-names>J.</given-names></name><name><surname>Takeshita</surname><given-names>L.</given-names></name><name><surname>Ortega-Rivera</surname><given-names>N.D.</given-names></name><etal/></person-group><article-title>Allele frequency net database (AFND) 2020 update: gold-standard data classification, open access genotype data and new query tools</article-title><source>Nucleic Acids Res.</source><volume>48</volume><issue>D1</issue><year>2020</year><fpage>D783</fpage><lpage>D788</lpage><pub-id pub-id-type="pmid">31722398</pub-id>
</element-citation></ref><ref id="bib30"><label>30</label><element-citation publication-type="journal" id="sref30"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>J.</given-names></name><name><surname>Malik</surname><given-names>A.</given-names></name><name><surname>Parham</surname><given-names>P.</given-names></name><name><surname>Bodmer</surname><given-names>J.G.</given-names></name><name><surname>Marsh</surname><given-names>S.G.</given-names></name></person-group><article-title>IMGT/HLA database--a sequence database for the human major histocompatibility complex</article-title><source>Tissue Antigens</source><volume>55</volume><issue>3</issue><year>2000</year><fpage>280</fpage><lpage>287</lpage><pub-id pub-id-type="pmid">10777106</pub-id>
</element-citation></ref><ref id="bib31"><label>31</label><element-citation publication-type="journal" id="sref31"><person-group person-group-type="author"><name><surname>Barker</surname><given-names>D.J.</given-names></name><name><surname>Maccari</surname><given-names>G.</given-names></name><name><surname>Georgiou</surname><given-names>X.</given-names></name><name><surname>Cooper</surname><given-names>M.A.</given-names></name><name><surname>Flicek</surname><given-names>P.</given-names></name><name><surname>Robinson</surname><given-names>J.</given-names></name><etal/></person-group><article-title>The IPD-IMGT/HLA database</article-title><source>Nucleic Acids Res.</source><volume>51</volume><issue>D1</issue><year>2023</year><fpage>D1053</fpage><lpage>D1060</lpage><pub-id pub-id-type="pmid">36350643</pub-id>
</element-citation></ref><ref id="bib32"><label>32</label><element-citation publication-type="journal" id="sref32"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>J.</given-names></name><name><surname>Barker</surname><given-names>D.J.</given-names></name><name><surname>Marsh</surname><given-names>S.G.E.</given-names></name></person-group><article-title>25 years of the IPD-IMGT/HLA database</article-title><source>HLA</source><volume>103</volume><issue>6</issue><year>2024</year><object-id pub-id-type="publisher-id">e15549</object-id></element-citation></ref><ref id="bib33"><label>33</label><element-citation publication-type="journal" id="sref33"><person-group person-group-type="author"><name><surname>Halldorsson</surname><given-names>B.V.</given-names></name><name><surname>Eggertsson</surname><given-names>H.P.</given-names></name><name><surname>Moore</surname><given-names>K.H.S.</given-names></name><name><surname>Hauswedell</surname><given-names>H.</given-names></name><name><surname>Eiriksson</surname><given-names>O.</given-names></name><name><surname>Ulfarsson</surname><given-names>M.O.</given-names></name><etal/></person-group><article-title>The sequences of 150,119 genomes in the UK Biobank</article-title><source>Nature</source><volume>607</volume><issue>7920</issue><year>2022</year><fpage>732</fpage><lpage>740</lpage><pub-id pub-id-type="pmid">35859178</pub-id>
</element-citation></ref><ref id="bib34"><label>34</label><element-citation publication-type="journal" id="sref34"><person-group person-group-type="author"><name><surname>Karczewski</surname><given-names>K.J.</given-names></name><name><surname>Francioli</surname><given-names>L.C.</given-names></name><name><surname>Tiao</surname><given-names>G.</given-names></name><name><surname>Cummings</surname><given-names>B.B.</given-names></name><name><surname>Alfoldi</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>Q.</given-names></name><etal/></person-group><article-title>The mutational constraint spectrum quantified from variation in 141,456 humans</article-title><source>Nature</source><volume>581</volume><issue>7809</issue><year>2020</year><fpage>434</fpage><lpage>443</lpage><pub-id pub-id-type="pmid">32461654</pub-id>
</element-citation></ref><ref id="bib35"><label>35</label><element-citation publication-type="journal" id="sref35"><person-group person-group-type="author"><name><surname>Metsalu</surname><given-names>T.</given-names></name><name><surname>Vilo</surname><given-names>J.</given-names></name></person-group><article-title>ClustVis: a web tool for visualizing clustering of multivariate data using Principal Component Analysis and heatmap</article-title><source>Nucleic Acids Res.</source><volume>43</volume><issue>W1</issue><year>2015</year><fpage>W566</fpage><lpage>W570</lpage><pub-id pub-id-type="pmid">25969447</pub-id>
</element-citation></ref><ref id="bib36"><label>36</label><element-citation publication-type="journal" id="sref36"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Z.</given-names></name><name><surname>Ren</surname><given-names>J.</given-names></name><name><surname>Dai</surname><given-names>C.</given-names></name><name><surname>Kannapell</surname><given-names>C.C.</given-names></name><name><surname>Wang</surname><given-names>H.</given-names></name><name><surname>Gaskin</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Nature of T cell epitopes in lupus antigens and HLA-DR determines autoantibody initiation and diversification</article-title><source>Ann. Rheum. Dis.</source><volume>78</volume><issue>3</issue><year>2019</year><fpage>380</fpage><lpage>390</lpage><pub-id pub-id-type="pmid">30254034</pub-id>
</element-citation></ref><ref id="bib37"><label>37</label><element-citation publication-type="journal" id="sref37"><person-group person-group-type="author"><name><surname>Barcellos</surname><given-names>L.F.</given-names></name><name><surname>May</surname><given-names>S.L.</given-names></name><name><surname>Ramsay</surname><given-names>P.P.</given-names></name><name><surname>Quach</surname><given-names>H.L.</given-names></name><name><surname>Lane</surname><given-names>J.A.</given-names></name><name><surname>Nititham</surname><given-names>J.</given-names></name><etal/></person-group><article-title>High-density SNP screening of the major histocompatibility complex in systemic lupus erythematosus demonstrates strong evidence for independent susceptibility regions</article-title><source>PLoS Genet.</source><volume>5</volume><issue>10</issue><year>2009</year><object-id pub-id-type="publisher-id">e1000696</object-id></element-citation></ref><ref id="bib38"><label>38</label><element-citation publication-type="journal" id="sref38"><person-group person-group-type="author"><name><surname>Miglioranza</surname><given-names>Scavuzzi B.</given-names></name><name><surname>van Drongelen</surname><given-names>V.</given-names></name><name><surname>Kaur</surname><given-names>B.</given-names></name><name><surname>Fox</surname><given-names>J.C.</given-names></name><name><surname>Liu</surname><given-names>J.</given-names></name><name><surname>Mesquita-Ferrari</surname><given-names>R.A.</given-names></name><etal/></person-group><article-title>The lupus susceptibility allele DRB1&#x02217;03:01 encodes a disease-driving epitope</article-title><source>Commun. Biol.</source><volume>5</volume><issue>1</issue><year>2022</year><fpage>751</fpage><pub-id pub-id-type="pmid">35902632</pub-id>
</element-citation></ref><ref id="bib39"><label>39</label><element-citation publication-type="journal" id="sref39"><person-group person-group-type="author"><name><surname>Batchelor</surname><given-names>J.R.</given-names></name><name><surname>Fielder</surname><given-names>A.H.</given-names></name><name><surname>Walport</surname><given-names>M.J.</given-names></name><name><surname>David</surname><given-names>J.</given-names></name><name><surname>Lord</surname><given-names>D.K.</given-names></name><name><surname>Davey</surname><given-names>N.</given-names></name><etal/></person-group><article-title>Family study of the major histocompatibility complex in HLA DR3 negative patients with systemic lupus erythematosus</article-title><source>Clin. Exp. Immunol.</source><volume>70</volume><issue>2</issue><year>1987</year><fpage>364</fpage><lpage>371</lpage><pub-id pub-id-type="pmid">3501348</pub-id>
</element-citation></ref><ref id="bib40"><label>40</label><element-citation publication-type="journal" id="sref40"><person-group person-group-type="author"><name><surname>Graham</surname><given-names>R.R.</given-names></name><name><surname>Ortmann</surname><given-names>W.</given-names></name><name><surname>Rodine</surname><given-names>P.</given-names></name><name><surname>Espe</surname><given-names>K.</given-names></name><name><surname>Langefeld</surname><given-names>C.</given-names></name><name><surname>Lange</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Specific combinations of HLA-DR2 and DR3 class II haplotypes contribute graded risk for disease susceptibility and autoantibodies in human SLE</article-title><source>Eur. J. Hum. Genet.</source><volume>15</volume><issue>8</issue><year>2007</year><fpage>823</fpage><lpage>830</lpage><pub-id pub-id-type="pmid">17406641</pub-id>
</element-citation></ref><ref id="bib41"><label>41</label><element-citation publication-type="journal" id="sref41"><person-group person-group-type="author"><name><surname>Raj</surname><given-names>P.</given-names></name><name><surname>Rai</surname><given-names>E.</given-names></name><name><surname>Song</surname><given-names>R.</given-names></name><name><surname>Khan</surname><given-names>S.</given-names></name><name><surname>Wakeland</surname><given-names>B.E.</given-names></name><name><surname>Viswanathan</surname><given-names>K.</given-names></name><etal/></person-group><article-title>Regulatory polymorphisms modulate the expression of HLA class II molecules and promote autoimmunity</article-title><source>Elife</source><volume>5</volume><year>2016</year></element-citation></ref><ref id="bib42"><label>42</label><element-citation publication-type="journal" id="sref42"><person-group person-group-type="author"><name><surname>Kawasaki</surname><given-names>A.</given-names></name><name><surname>Kusumawati</surname><given-names>P.A.</given-names></name><name><surname>Kawamura</surname><given-names>Y.</given-names></name><name><surname>Kondo</surname><given-names>Y.</given-names></name><name><surname>Kusaoi</surname><given-names>M.</given-names></name><name><surname>Amano</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Genetic dissection of HLA-DRB1&#x02217;15:01 and XL9 region variants in Japanese patients with systemic lupus erythematosus: primary role for HLA-DRB1&#x02217;15:01</article-title><source>RMD Open</source><volume>9</volume><issue>2</issue><year>2023</year></element-citation></ref><ref id="bib43"><label>43</label><element-citation publication-type="journal" id="sref43"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J.Y.</given-names></name><name><surname>Wu</surname><given-names>Y.L.</given-names></name><name><surname>Mok</surname><given-names>M.Y.</given-names></name><name><surname>Wu</surname><given-names>Y.J.</given-names></name><name><surname>Lintner</surname><given-names>K.E.</given-names></name><name><surname>Wang</surname><given-names>C.M.</given-names></name><etal/></person-group><article-title>Effects of complement C4 gene copy number variations, size dichotomy, and C4A deficiency on genetic risk and clinical presentation of systemic lupus erythematosus in east asian populations</article-title><source>Arthritis Rheumatol.</source><volume>68</volume><issue>6</issue><year>2016</year><fpage>1442</fpage><lpage>1453</lpage><pub-id pub-id-type="pmid">26814708</pub-id>
</element-citation></ref><ref id="bib44"><label>44</label><element-citation publication-type="journal" id="sref44"><person-group person-group-type="author"><name><surname>Kamitaki</surname><given-names>N.</given-names></name><name><surname>Sekar</surname><given-names>A.</given-names></name><name><surname>Handsaker</surname><given-names>R.E.</given-names></name><name><surname>de Rivera</surname><given-names>H.</given-names></name><name><surname>Tooley</surname><given-names>K.</given-names></name><name><surname>Morris</surname><given-names>D.L.</given-names></name><etal/></person-group><article-title>Complement genes contribute sex-biased vulnerability in diverse disorders</article-title><source>Nature</source><volume>582</volume><issue>7813</issue><year>2020</year><fpage>577</fpage><lpage>581</lpage><pub-id pub-id-type="pmid">32499649</pub-id>
</element-citation></ref><ref id="bib45"><label>45</label><element-citation publication-type="journal" id="sref45"><person-group person-group-type="author"><name><surname>Paradowska-Gorycka</surname><given-names>A.</given-names></name><name><surname>Roszak</surname><given-names>M.</given-names></name><name><surname>Stypinska</surname><given-names>B.</given-names></name><name><surname>Lutkowska</surname><given-names>A.</given-names></name><name><surname>Walczyk</surname><given-names>M.</given-names></name><name><surname>Olesinska</surname><given-names>M.</given-names></name><etal/></person-group><article-title>IL-6 and TGF-beta gene polymorphisms, their serum levels, as well as HLA profile, in patients with systemic lupus erythematosus</article-title><source>Clin. Exp. Rheumatol.</source><volume>37</volume><issue>6</issue><year>2019</year><fpage>963</fpage><lpage>975</lpage><pub-id pub-id-type="pmid">30943147</pub-id>
</element-citation></ref><ref id="bib46"><label>46</label><element-citation publication-type="journal" id="sref46"><person-group person-group-type="author"><name><surname>Acosta-Colman</surname><given-names>I.</given-names></name><name><surname>Morel</surname><given-names>Z.</given-names></name><name><surname>Ayala Lugo</surname><given-names>A.</given-names></name><name><surname>Jolly</surname><given-names>V.</given-names></name><name><surname>De Guillen</surname><given-names>I.</given-names></name><name><surname>Langjahr</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Clinical features and genetic biomarkers associated with different phenotypes of systemic lupus erythematosus in Paraguayan patients</article-title><source>Reumatismo</source><volume>75</volume><issue>2</issue><year>2023</year></element-citation></ref><ref id="bib47"><label>47</label><element-citation publication-type="journal" id="sref47"><person-group person-group-type="author"><name><surname>Reinharz</surname><given-names>D.</given-names></name><name><surname>Tiercy</surname><given-names>J.M.</given-names></name><name><surname>Mach</surname><given-names>B.</given-names></name><name><surname>Jeannet</surname><given-names>M.</given-names></name></person-group><article-title>Absence of DRw15/3 and of DRw15/7 heterozygotes in Caucasian patients with systemic lupus erythematosus</article-title><source>Tissue Antigens</source><volume>37</volume><issue>1</issue><year>1991</year><fpage>10</fpage><lpage>15</lpage><pub-id pub-id-type="pmid">2063393</pub-id>
</element-citation></ref><ref id="bib48"><label>48</label><element-citation publication-type="journal" id="sref48"><person-group person-group-type="author"><name><surname>Bang</surname><given-names>S.Y.</given-names></name><name><surname>Choi</surname><given-names>J.Y.</given-names></name><name><surname>Park</surname><given-names>S.</given-names></name><name><surname>Choi</surname><given-names>J.</given-names></name><name><surname>Hong</surname><given-names>S.J.</given-names></name><name><surname>Lee</surname><given-names>H.S.</given-names></name><etal/></person-group><article-title>Brief report: influence of HLA-DRB1 susceptibility alleles on the clinical subphenotypes of systemic lupus erythematosus in Koreans</article-title><source>Arthritis Rheumatol.</source><volume>68</volume><issue>5</issue><year>2016</year><fpage>1190</fpage><lpage>1196</lpage><pub-id pub-id-type="pmid">26663868</pub-id>
</element-citation></ref><ref id="bib49"><label>49</label><element-citation publication-type="journal" id="sref49"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>W.A.</given-names></name><name><surname>Scopelitis</surname><given-names>E.</given-names></name><name><surname>Michalski</surname><given-names>J.P.</given-names></name></person-group><article-title>Association of HLA-DR7 with both antibody to SSA(Ro) and disease susceptibility in blacks with systemic lupus erythematosus</article-title><source>J. Rheumatol.</source><volume>11</volume><issue>5</issue><year>1984</year><fpage>653</fpage><lpage>657</lpage><pub-id pub-id-type="pmid">6334744</pub-id>
</element-citation></ref><ref id="bib50"><label>50</label><element-citation publication-type="journal" id="sref50"><person-group person-group-type="author"><name><surname>Savi</surname><given-names>M.</given-names></name><name><surname>Ferraccioli</surname><given-names>G.F.</given-names></name><name><surname>Neri</surname><given-names>T.M.</given-names></name><name><surname>Zanelli</surname><given-names>P.</given-names></name><name><surname>Dall'Aglio</surname><given-names>P.P.</given-names></name><name><surname>Tincani</surname><given-names>A.</given-names></name><etal/></person-group><article-title>HLA-DR antigens and anticardiolipin antibodies in northern Italian systemic lupus erythematosus patients</article-title><source>Arthritis Rheum.</source><volume>31</volume><issue>12</issue><year>1988</year><fpage>1568</fpage><lpage>1570</lpage><pub-id pub-id-type="pmid">3196369</pub-id>
</element-citation></ref><ref id="bib51"><label>51</label><element-citation publication-type="journal" id="sref51"><person-group person-group-type="author"><name><surname>Ramsey-Goldman</surname><given-names>R.</given-names></name><name><surname>Li</surname><given-names>J.</given-names></name><name><surname>Dervieux</surname><given-names>T.</given-names></name><name><surname>Alexander</surname><given-names>R.V.</given-names></name></person-group><article-title>Cell-bound complement activation products in SLE</article-title><source>Lupus Sci Med</source><volume>4</volume><issue>1</issue><year>2017</year><object-id pub-id-type="publisher-id">e000236</object-id></element-citation></ref><ref id="bib52"><label>52</label><element-citation publication-type="journal" id="sref52"><person-group person-group-type="author"><name><surname>Christiansen</surname><given-names>F.T.</given-names></name><name><surname>Zhang</surname><given-names>W.J.</given-names></name><name><surname>Griffiths</surname><given-names>M.</given-names></name><name><surname>Mallal</surname><given-names>S.A.</given-names></name><name><surname>Dawkins</surname><given-names>R.L.</given-names></name></person-group><article-title>Major histocompatibility complex (MHC) complement deficiency, ancestral haplotypes and systemic lupus erythematosus (SLE): C4 deficiency explains some but not all of the influence of the MHC</article-title><source>J. Rheumatol.</source><volume>18</volume><issue>9</issue><year>1991</year><fpage>1350</fpage><lpage>1358</lpage><pub-id pub-id-type="pmid">1757937</pub-id>
</element-citation></ref><ref id="bib53"><label>53</label><element-citation publication-type="journal" id="sref53"><person-group person-group-type="author"><name><surname>Fernando</surname><given-names>M.M.</given-names></name><name><surname>Boteva</surname><given-names>L.</given-names></name><name><surname>Morris</surname><given-names>D.L.</given-names></name><name><surname>Zhou</surname><given-names>B.</given-names></name><name><surname>Wu</surname><given-names>Y.L.</given-names></name><name><surname>Lokki</surname><given-names>M.L.</given-names></name><etal/></person-group><article-title>Assessment of complement C4 gene copy number using the paralog ratio test</article-title><source>Hum. Mutat.</source><volume>31</volume><issue>7</issue><year>2010</year><fpage>866</fpage><lpage>874</lpage><pub-id pub-id-type="pmid">20506482</pub-id>
</element-citation></ref><ref id="bib54"><label>54</label><element-citation publication-type="journal" id="sref54"><person-group person-group-type="author"><name><surname>Chi</surname><given-names>C.</given-names></name><name><surname>Shao</surname><given-names>X.</given-names></name><name><surname>Rhead</surname><given-names>B.</given-names></name><name><surname>Gonzales</surname><given-names>E.</given-names></name><name><surname>Smith</surname><given-names>J.B.</given-names></name><name><surname>Xiang</surname><given-names>A.H.</given-names></name><etal/></person-group><article-title>Admixture mapping reveals evidence of differential multiple sclerosis risk by genetic ancestry</article-title><source>PLoS Genet.</source><volume>15</volume><issue>1</issue><year>2019</year><object-id pub-id-type="publisher-id">e1007808</object-id></element-citation></ref><ref id="bib55"><label>55</label><element-citation publication-type="journal" id="sref55"><person-group person-group-type="author"><name><surname>Antal</surname><given-names>Z.</given-names></name><name><surname>Jarchum</surname><given-names>I.</given-names></name><name><surname>DiLorenzo</surname><given-names>T.P.</given-names></name></person-group><article-title>HLA class I supertypes in type 1 diabetic children in an urban children's hospital</article-title><source>Ann. N. Y. Acad. Sci.</source><volume>1150</volume><year>2008</year><fpage>86</fpage><lpage>89</lpage><pub-id pub-id-type="pmid">19120273</pub-id>
</element-citation></ref><ref id="bib56"><label>56</label><element-citation publication-type="journal" id="sref56"><person-group person-group-type="author"><name><surname>Friese</surname><given-names>M.A.</given-names></name><name><surname>Jakobsen</surname><given-names>K.B.</given-names></name><name><surname>Friis</surname><given-names>L.</given-names></name><name><surname>Etzensperger</surname><given-names>R.</given-names></name><name><surname>Craner</surname><given-names>M.J.</given-names></name><name><surname>McMahon</surname><given-names>R.M.</given-names></name><etal/></person-group><article-title>Opposing effects of HLA class I molecules in tuning autoreactive CD8+ T cells in multiple sclerosis</article-title><source>Nat. Med.</source><volume>14</volume><issue>11</issue><year>2008</year><fpage>1227</fpage><lpage>1235</lpage><pub-id pub-id-type="pmid">18953350</pub-id>
</element-citation></ref></ref-list><sec sec-type="data-availability" id="da0010"><title>Data availability</title><p id="p0030">Data will be made available on request.</p></sec><ack id="ack0010"><title>Acknowledgements</title><p id="p0200">This project was supported by LUPUS UK, <funding-source id="gs2"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100012041</institution-id><institution>Versus Arthritis</institution></institution-wrap></funding-source>
<funding-source id="gs3">UK</funding-source> and the UK's Experimental Arthritis Treatment Centre for Children (EATC4Children), the <funding-source id="gs4"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100000272</institution-id><institution>NIHR</institution></institution-wrap></funding-source> Great Ormond Street <funding-source id="gs5">Biomedical Research Centre</funding-source> (<funding-source id="gs6"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100019256</institution-id><institution>NIHR GOSH BRC</institution></institution-wrap></funding-source>), the <funding-source id="gs7"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100000272</institution-id><institution>NIHR</institution></institution-wrap></funding-source> Alder Hey <funding-source id="gs8"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100018835</institution-id><institution>Clinical Research Facility (NIHR</institution></institution-wrap></funding-source> AH CRF), and the French referral medical laboratory (LBMR SSc and SLE). The UK's EATC4Children is supported by <funding-source id="gs12"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100012041</institution-id><institution>Versus Arthritis</institution></institution-wrap></funding-source>
<funding-source id="gs13">UK</funding-source>, the <funding-source id="gs14"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100000836</institution-id><institution>University of Liverpool</institution></institution-wrap></funding-source> and Alder Hey Children's Foundation Trust. The UK JSLE Cohort Study and Repository is supported by LUPUS UK and <funding-source id="gs16"><institution-wrap><institution-id institution-id-type="doi">10.13039/501100012041</institution-id><institution>Versus Arthritis</institution></institution-wrap></funding-source> UK. The authors would like to acknowledge all patients and their families for participating in the UK JSLE Cohort Study and Repository. Specifically, the authors are grateful to all the support given by the entire multi-disciplinary team within each of the paediatric centres who are part of the UK JSLE Study Group (<ext-link ext-link-type="uri" xlink:href="https://www.liverpool.ac.uk/translational-medicine/research/ukjsle/jsle/" id="intref0055">https://www.liverpool.ac.uk/translational-medicine/research/ukjsle/jsle/</ext-link>).</p></ack></back></article>